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Abstract
The androgen receptor complex plays an essential role in prostate cancer progression due
to exploitation of the androgen receptor (AR) as a transcription factor. The final stage of the
receptor complex consists of a dimerized receptor, a dimeric heat shock protein (Hsp90), the
cochaperone p23, and an immunophilin. Hormone-dependent prostate cancer progresses due to
key interactions between the androgen receptor complex and its ligand 5α-dihydrotestosterone
(DHT). While current treatments focus on blocking the androgen receptor-ligand interactions,
these therapies are no longer effective in advanced stage, hormone-refractory prostate cancer
(HRPC).

Therefore, we have been interested in targeting other members of the androgen

receptor complex and signaling cascade, namely the immunophilin FK506 Binding Protein 52
(FKBP52) and the cell signaling protein β-catenin. FKBP52 has the ability to potentiate activity
of the androgen, progesterone, and glucocorticoid receptors and is a novel prostate cancer
biomarker. β-catenin is a member of the cellular adhesion complex with E-cadherin in healthy
cells, but in aberrant situations, β-catenin actively promotes cancer progression and invasion.
Our data in FKBP52 knockout mouse embryonic fibroblasts (52 KO MEF) and FKBP52
Knock down 22RV1 cell lines suggests that FKBP52 and β-catenin work in tandem to synergize
AR transcriptional activity. When AR, FKBP52, and β-catenin are cotransfected, AR signaling
synergizes under levels of very low DHT, as tracked by luciferase reporter assays. The synergy
is so great that it dwarfs the potentiation of FKP52 and regulation of β-catenin alone. According
to pull down assays, FKBP52 and β-catenin can bind in the absence of other proteins. Luciferase
assays of mutant FKBP52 proteins suggest that FKBP52’s binding to β-catenin involves the
FKBP52 proline-rich loop but acts independently of Hsp90 binding. Interestingly, it appears that
this synergistic effect is DNA sequence-specific, suggesting that the regulation by these proteins
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occurs at the transcriptional level. We have successfully abrogated the synergism of these
proteins using a small molecule inhibitor compound MJC13, developed in our laboratory.
According to surface plasmon resonance studies, this molecule binds the androgen receptor at the
Binding Function 3 (BF-3) regulatory surface, the putative interaction surface for FKBP52
regulation of receptor. MJC13 potency is not improved with the combined administration of the
anti-androgen Bicalutamide or the Hsp90 inhibitors KU174 or 17AAG. Studies in 22RV1
prostate cancer cells comparing control cells to FKBP52 knock down cells reveal the obligatory
role of FKBP52 in β-catenin potentiation of AR.

In the absence of FKBP52, β-catenin

transfection barely increases AR signaling over basal levels, but when FKBP52 is present, βcatenin is a strong coactivator of transcription by AR.
development of new prostate cancer therapies.
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Chapter 1: Introduction

1

1.1 A BASIC MODEL OF ANDROGEN RECEPTOR SIGNALING PATHWAYS
The androgen receptor (AR) is a member of the Type I steroid hormone receptor (SHR)
family, also comprised of glucocorticoid receptor (GR), mineralocorticoid receptor (MR),
progesterone receptor (PR), and estrogen receptor (ER) (1). AR is a 110 kDa protein which is
transcribed from a gene located on the X chromosome (2). Because of its importance in the
regulation of androgen-mediated genes, AR localization is tightly regulated. The androgen
receptor, like other SHRs, does not exist as a lone protein in the cytoplasm; it is always found in
conjunction with other proteins, which regulate both its conformational state and localization.
The proteins of the androgen receptor complex associate with the receptor in the cytoplasm to
maintain the receptor in an appropriate conformation to bind ligand as well as to localize the
receptor in the cytoplasm until ligand binding occurs. The classic model maintains that the
receptor dissociates from the complex upon hormone binding and travels to the nucleus.
However, the discovery that the entire mature MR complex of proteins, including heat shock
protein 90 (Hsp90), p23, MR, and FK506 Binding Protein 52 (FKBP52), is capable of traveling
to the nucleus (3) certainly arouses the possibility that the AR complex could translocate as well.
Hsp90-bound steroid hormone receptors are incapable of binding DNA (4). Therefore, it is safe
to say that while the location of detachment from the Hsp90 complex is still being determined, it
is dissociated from the complex when it binds DNA.
Androgens, the ligands for AR, are signaling molecules generated in the adrenal cortex,
ovaries, and testes through transformations of cholesterol.

Bound by carrier molecules,

androgens travel to target tissues in the body through the bloodstream (5). Once androgens
contact target tissues, they travel by diffusion into the cell. It is difficult to estimate the amount
of testosterone that actually reaches target tissues in vivo, since the bioavailability of the
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hormone is regulated by sex hormone binding globulin (SHBG). While androgen levels (such as
5α-dihydrotestosterone (DHT) and androstanediol glucuronide (AAG)) can be quantified from
serum samples, it is difficult to generalize about “normal” levels of androgens due to
interpersonal variability in clearance rates and bioavailability. Increased levels of testosterone or
decreased levels of SHBG are associated with prostate cancer (6).
The conformation of the steroid hormone receptor must be primed for hormone binding
by a series of events involving a number of chaperones and cochaperones, as seen in Figure 1.1.
This figure is primarily based upon studies of GR and ER (4, 7). As soon as the receptor leaves
the ribosome, the receptor complexes with chaperones such as the heat shock proteins (8). The
early complex is characterized by the association of Hsp40 and Hsp70 with the receptor. Hsp40
initiates Hsp70’s ATPase activity, activating Hsp70 to chaperone the receptor into an
appropriately folded state. In the intermediate complex, the receptor binds the adaptors Hsp
Interacting Protein (HIP) and Hsp Organizing Protein (HOP) or the chaperone cofactors BCL-2
athanogene-1 (BAG-1) and COOH terminus of the Hsp70-interacting protein (CHIP) (7). If the
receptor has not folded properly, BAG-1 transfers the receptor complex to CHIP, a ubiquitin
ligase which tags the protein for the proteasomal degradation pathway (9). However, if the
receptor is in an appropriate conformation, Hsp40 is displaced with HIP, a protein that increases
the stability of the ADP-bound form of Hsp70. HOP also binds and promotes the transfer of the
receptor from Hsp70 to the Hsp90 dimer.
The mature complex is characterized by the association of the receptor with the Hsp90
dimer, the cochaperone p23 which stabilizes the Hsp90 interaction with the receptor by keeping
it in an ATP-bound state, and an immunophilin (4). Immunophilins are proteins which bind
immunosuppressive drugs but may or may not participate in immunosuppression when bound to
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Figure 1.1: Steroid Hormone Receptor Maturation Cycle

Figure 1.1 depicts the association of the steroid hormone receptor with chaperones and
cochaperones in the early, intermediate, and mature steroid hormone receptor complexes.
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those drugs. Immunophilins which associate with the steroid hormone receptors to either
increase or decrease their activity as transcription factors are FKBP51, FKBP52, Cyclophilin 40
(Cyp40), or serine/threonine protein phosphatase 5 (PP5) (4).
Formation of the mature complex is required to prime the receptor for high-affinity
binding of hormone (10). The immunophilins FKBP51 and FKBP52 may bind AR at this stage
of the complex. FKBP52 is associated with potentiation of AR (11), GR (12), and PR (13)
signaling in response to hormone, whereas FKBP51 normally antagonizes steroid receptor
signaling (10).
Figure 1.2 presents a summary of the receptor’s interactions with other factors in the
non-cancerous cell. When hormone enters the cell, it binds the mature complex of the receptor,
presumably in the cytoplasm. While Hsp90 is indeed required for the initial binding of the
receptor to hormone, it is not required for transcriptional events in the nucleus. Following
hormone binding, the receptor homodimerizes by attaching DNA Binding Domain (DBD) to
DBD, Ligand Binding Domain (LBD) to LBD, and N-terminus to C-terminus. The receptor then
binds hormone response elements within the DNA at the conserved consensus site shared by AR,
PR, GR, and MR. Later the receptor returns to the cytoplasm where it enters the receptor
maturation cycle again, destined for either successive hormone binding or degradation (2).

1.2 ANDROGEN RECEPTOR ISOFORMS AND STRUCTURE
The androgen receptor exists in multiple isoforms in normal tissues. Androgen receptor isoforms
A and B are the most prevalent forms found in normal human tissues and are generated by
alternative splicing (14). AR-A is an 87kDa, truncated form of the receptor, whereas AR-B is a
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110 kDa protein which contains 23 additional amino acids at the N-terminal domain.
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Figure 1.2: Steroid Hormone Receptor Signaling Pathway

Figure 1.2 is a depiction of the hormone-induced steroid hormone receptor signaling pathway.
Hormone binds the mature steroid hormone receptor (SHR) complex, causing receptor
dimerization and translocation to the nucleus, where the receptor binds response elements to
activate transcription.
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Transcription of isoform A can be initiated by the internal translation start site at the Met188 residue. AR-B represents 91% of the AR species expressed in adult genital fibroblast tissue.
AR-B contains a polyglutamine repeat tract that is absent in AR-A (15). AR-B exists in the
cytoplasm as a receptor primarily to androgens and is also found in the nucleus where it serves as
a transcription factor (2). In addition to isoforms A and B, castrate-resistant prostate cancer
tissues display multiple AR splice variants and truncation mutants (16).
A proper investigation of putative interactions of the androgen receptor with other
proteins requires an understanding of AR’s structure. The androgen receptor has three main
domains: the N-terminal domain, the DNA binding domain, and the ligand binding domain
located at the C-terminus (2), as seen in Figure 1.3
The N-terminal domain (NTD) is the least conserved domain of the SHRs, with only 15%
homology between the different receptors (2, 17).

It contains the major activation site

Activation Function 1 (AF-1). In the androgen receptor, the N-terminal domain contains a
segment of polymorphic glycine and glutamate repeats. It also contains a FQNLF motif that
allows the NTD to interact with the C-terminal domain (CTD), influencing trans-activation of the
receptor (2). Additionally, AR contains the small ubiquitination like modifier (SUMO)ylation
sites K386 and K520, and it is believed that SUMOylation of these sites causes transcriptional
repression (18).
AR’s DNA binding domain is a stretch of approximately 800 amino acids characterized
by two zinc finger motifs.

The DBD is highly conserved among the nuclear receptors.

Therefore, the hormone response elements to which all nuclear receptors bind are also conserved
(19, 20). AR binds DNA more tightly than any other nuclear receptor due to its higher affinitydimerization (2). The first zinc finger of AR contacts the major groove of DNA, and this region
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Figure 1.3: Domains of the Androgen Receptor

Major domains of the androgen receptor are highlighted. The regulatory regions and nuclear
localization sequences are depicted below the representation of the corresponding AR domain.
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of DNA is termed the proximal (P) box. The second zinc finger is responsible for ensuring that
dimerization occurs stably in response to binding to DNA and that the dimer is in the proper
orientation to contact the hormone response element (HRE); this region of the DNA is termed
the distal (D) box (2, 5).
The hinge region is located between the DNA binding domain and the ligand binding
domain and is important for cellular localization and degradation. This region contains the
nuclear localization and export sequences. The androgen receptor associates with importin α for
nuclear import (2). It appears that the immunophilin FKBP52 assists with nuclear import of the
receptor in some cases (3, 21, 22). There is a potential proline, glutamic acid, serine, and
threonine-rich (PEST) sequence in the hinge region of AR which may be involved in protein
degradation pathways. Additionally, the hinge region undergoes post-translational modifications
such as phosphorylation by Mitogen Activated Protein Kinase (MEK-K) kinases to assist in
translocation and acetylation by p300/CBP-associated factor (pCAF), HIV-Tat Interacting
Protein (Tip60), and CCAAT Binding Factor (CBF)/p300 (2). Acetylation of AR is associated
with decreased activation of receptor, decreased cofactor recruitment to the promoter, increased
recruitment of transcriptional co-repressors, and decreased nuclear AR localization (23).
The ligand binding domain of AR, as seen in Figure 1.4, is composed of eleven α-helices
comprising an internal ligand binding cavity (20). The helices are named one through twelve
(there is no second helix, however) to keep the nomenclature consistent between different
receptors. The natural hormone ligands for the androgen receptor are DHT and testosterone (2).
Ligand contacts 18 crucial residues of the ligand binding domain on helices 3, 5, and 11; this
internal binding site is known as Binding Function 1 BF-1 [10, 22, 34-35]. Helix 12 is a gate on
the ligand binding domain; it opens to permit ligand binding and closes once ligand has bound.
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Figure 1.4: Ligand Binding Domain of the Androgen Receptor bound to R1881

Figure 1.4 is a graphic adapted from the Androgen Receptor Gene Mutations Database
(http://androgendb.mcgill.ca/ARmodel.jpg), designed by Dr. JH Wu of the LDI Molecular
Modeling Laboratory. The image was generated through UCSF Chimera Version 1.5 using PDB
1XQ3. Helices are labeled 1 through 12 and appear in different colors. The bound synthetic
agonist R1881 (ball and stick) appears in yellow. The LBD is oriented to the BF3 surface. The
key residues of the putative FKBP52 binding surface F673(red), P723 (tan), and C806
(cornflower blue) project from the BF3 surface as seen in the figure.
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Once ligand binds, a hydrophobic region known as Activation Function 2 (AF-2) surfaces on the
ligand binding domain, allowing receptor dimerization (24) and recruitment of coactivator
binding via LXXLL binding motifs (2, 25, 26). Furthermore, the FXXLF motifs of alpha helices
in nuclear receptor (NR)-boxes of coregulators such as the steroid receptor coactivator 2 (SRC2)
and AR Associated Protein 70 (ARA70) also facilitate binding to this surface (27, 28).
Further study of the role of the receptor, its coregulators, and modifications to the
androgen receptor at the post-transcriptional and translational levels are all topics for study in
endocrine receptor research.
1.3 HSP90
Hsp90 is a chaperone with more than 200 client proteins, including steroid hormone
receptors, stress response proteins, and cellular cascade members. Hsp90 complexes with Hsp70
and co-chaperone proteins to form the dynamic Hsp90 chaperone machine. The function of
Hsp90 as a chaperone can be described in three parts: assisting in the folding of proteins,
resisting aggregation, and participating in the association and assembly of multimeric proteins
such as steroid hormone receptor complexes. Hsp90 functions to maintain cellular homeostasis,
to drive heat shock response via activation of Heat Shock Transcription Factor 1 (HSF1) activity,
and even to regulate transcriptional events (29).
A monomer of Hsp90 consists of three domains. The N-terminal domain contains an
ATP binding site, which is critical for chaperone function. The middle domain contacts client
proteins and also is responsible for ATPase activity. The C-terminal domain contains the motif
by which the chaperone protein dimerizes. The current model for Hsp90 chaperoning suggests
that Hsp90 begins in an open state in which the N-terminus does not have a nucleotide present,
and when ATP binds each of the N termini, it favors a shift of conformation, promoting an
12

interaction of the N termini together. Meanwhile, co-chaperones HOP or cell division cycle 37
homologue (CDC37) can bind and temporarily delay the N terminal dimerization.

These

proteins deliver client proteins such as steroid hormone receptors and protein kinases,
respectively. As Hsp90 dimerizes at the N-termini, it adopts a closed and contorted orientation.
Activator of Hsp90 ATPase1 (AHA1) binding promotes a favorable conformation of the
chaperone dimer for ATP hydrolysis. The p23 co-chaperone stabilizes this closed conformation
of the dimer. ATP is then hydrolyzed by the middle domain, and the ADP dissociates, triggering
the opening of the Hsp90 dimer for the binding of the next client protein (29). Figure 1.5 gives
a graphical depiction of the Hsp90 chaperoning cycle.
Hsp90 regulation can occur naturally via interactions with co-chaperones and posttranslational modifications. The co-chaperones of Hsp90 include but are not limited to HOP,
p23, Small Glutamine Rich Tetratricopeptide Repeat Protein 1 (SGT1), FKBP51, FKBP52,
CDC37, AHA1, Serine/Threonine Protein Phosphatase 5 (PP5), CHIP, Tetratricopeptide Repeatcontaining Protein associated with Hsp90 (TAH1) and protein interacting with Hsp90 (PIH1).
The effects of co-chaperone binding to Hsp90 are diverse, from delivering client proteins,
assisting in chaperoning activity via modulation of ATPase state, increasing functionality of
client proteins, decreasing client protein functionality, and promoting client protein degradation.
The dynamic interaction of Hsp90 with the net sum of its clients and co-chaperone proteins
determines the regulatory outcome of the interaction with client protein (29).
Post-translational modifications of Hsp90 include phosphorylation, acetylation, and Snitrosylation. Phosphorylation of Hsp90 is associated with Vascular Endothelial Growth Factor
2 (VEGF2)-induced angiogenesis, apoptosome formation, and kinase chaperoning.
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Figure 1.5: Hsp90 Binding Cycle

Figure 1.5 is a graphic modified from Figure 1, Nature Reviews Cancer 10, 537-549 (August
2010) | doi:10.1038/nrc2887. The Hsp90 dimer’s open conformation allows ATP to bind to the
N terminals of the protein, inducing association of HOP or CDC37 to deliver client proteins and
temporarily delay the clamping of the dimer’s N termini. AHA1 binding favors movement
towards ATP hydrolysis. P23 stabilizes a closed dimer conformation so that client protein is
maintained in association with Hsp90. ATP is hydrolyzed to ADP by the middle domain, and
ADP dissociates, allowing Hsp90 to adopt the open conformation once again.
14

It appears that acetylation is linked to effective binding of Hsp90 to p23, ATP, and client
proteins. S-nitrosylation can inhibit ATPase activity. (29).
Hsp90 has a well-established role in controlling cellular distribution of steroid hormone
receptors, in promoting ligand binding, and in helping to stabilize the complex (29). Some argue
that Hsp90 may also play a role in the nucleus. Indeed, three percent of all Hsp90 exists in the
nucleus (30). Hsp90 is known to interact at the nuclear level with B Cell Lymphoma 6 Protein
(BCL-6) and the proteins SET and MYND domain containing 2 and 3 (SMYD-2 and 3). Hsp90
binds BCL-6, forming a transcriptional repressor complex in the nucleus (31). Activity of the
histone methyltransferases SMYD-2 and SMYD 3 increases in the presence of their binding
partner Hsp90 in vitro (32).

Both SMYD-2 and SMYD-3 expression is increased in several

cancers (32, 33).
1.4 FKBP51 AND FKBP52
The immunophilins are a class of proteins, which are distinguished by their ability to bind
immusuppressive drugs through PPIase domains. Immunophilins can be further separated into
two categories according to immunosuppressive drug binding. Cyclophilins (CyP) bind the drug
cyclosporin-A, and FK506 binding proteins (FKBPs) bind rapamycin and FK506. The FKBPs
contain varying numbers of FK domains, and a subset binds Hsp90 (10).
Two members of the FKBP family which possess Hsp90 binding abilities are FKBP51
and FKBP52. FKBP51 and FKBP52 are 60% identical and approximately 70% similar in amino
acid conservation (34). Figure 1.6 shows a structural comparison of FKBP51 and FKBP52. The
proteins contain the same structural domains but differ visibly in the orientation of the
tetratricopeptide repeat (TPR) domains as seen through the crystal structure. The FK domains
are known as FKBP12-like domains.
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Figure 1.6: Structural Comparison of FKBP51 and FKBP52

X-ray crystallographic structures of FKBP51 and FKBP52. The three-dimensional structure of
the composite of two partial structures for human FKBP52 (protein databank numbers 1Q1C and
1P5Q) and the structure of human FKBP51 (protein databank number 1KT0) are shown in
ribbon format. Beta pleated sheets are in blue and alpha helices are in orange. The important
functional regions FK1, FK2, and TPR are illustrated. The figure was created, including
overlaying the two partial FKBP52 structures, using UCSF Chimera version 1.5. It appears as
Figure 1 in Trends in Endocrinology Metabolism, 2011 December; 22(12): 481–490.
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FK506 is the immunosuppressive drug which can bind any FKBP12-like domain but only
initiates immunosuppressive activity due to calcineurin inhibition through FKBP12 (35).
In both FKBP51 and FKBP52, the FK1 domain has functional peptidyl-prolyl cis-trans
isomerase (PPIase) activity and can bind the immunosuppressant FK506, whereas the FK2
domain is a PPIase-like domain with unknown function that lacks PPIase activity. FK1 regions
are conserved between the proteins, with the exception of a few amino acids at the proline-rich
loop of the PPIase domain. The hinge region connects FK1 to FK2 and is thus called the FK
loop. In FKBP52, the hinge region possesses a TEED phosphorylation site which is absent in
FKBP51 (10). Casein kinase II modifies this site at T143, which appears to be a regulation point
of FKBP52-receptor potentiation. It appears that when the phosphorylation-resistant mutant
T143E is constructed in FKBP52, the ability of FKBP52 to potentiate the action of receptors is
decreased but not completely abolished. It is believed that this mutation impacts the ability of
FKBP52’s linker region to form Hydrogen bonds properly (36).

Lastly, the TPR domain,

characterized by helix-loop-helix motifs in triplicate, is responsible for Hsp90 binding.

In

FKBP51, the TPR domain projects at an angle from the rest of the protein, but in FKBP52, the
TPR domain extends linearly with the rest of the protein. FKBP51 exhibits ionic bonding
between the FK2 and TPR domains, whereas FKBP52 lacks these bonds and is therefore more
flexible in nature (10).
At the animal level, much of our knowledge of FKBP51 and FKBP52 was gained
through studies of knockout mice. Male FKBP52 knockout mice (52KO) show varying degrees
of hypospadias, irregularities of genitalia, nipple enlargement, decreased size and abnormal
appearance of seminal vesicles and of the anterior prostate gland, and problems with testes
descent. Also, 52KO mice exhibit increased levels of corticosterone, although they circulate
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normal levels of androgens. The physiological abnormalities of the mice parallel those of human
pathologies in Androgen Insensitivity Syndrome. Male 52 KO mice are infertile, primarily due
to compromised AR signaling.

Dey and colleagues noted decreased spermatozoa motility,

decreased spermatozoa count, and decreased fertilization efficiency in male mice (37). 52 KO
female mice are infertile, although they lack external abnormalities and exhibit normal oogenesis
(11). Female infertility appears to be due to compromised PR signaling, thereby inhibiting
embryonic implantation in the uterus. 52 KO mice show only half the binding affinity of PR for
progesterone as wild-type mice (13). Interestingly, 52 KO mice exhibit 50% embryonic lethality
(11). On the other hand, FKBP51 KO mice do not exhibit physiological phenotypes from gene
deletion. However, when FKBP51 (fkbp5) and FKBP52 (fkbp4) are both knocked out, it results
in 100% embryonic lethality (38). This can be attributed to some redundancy of function of
FKBP51 and FKBP52.
The tissues of the 52KO mice were also sectioned and examined to further characterize
pathology and were compared to normal mice. FKBP52 was expressed in several wild type
mouse tissues but not in 52 KO mouse tissues. Histological sections revealed that AR was still
present in the nuclei of Leydig, peritubular myoid cells, and Sertoli cells of the testes, but AR
expression was decreased significantly in the sections.

Western blots revealed that the

expression profiles of other immunophilins (FKBP51, PP5, and Cyp40) were not significantly
changed due to the absence of FKBP52 in 52 KO mouse tissues, although AR expression
decreased slightly (11).

In another study by the Dey group, 52KO female mice exhibited

progesterone resistance in the uterus. When endometriotic uterine tissues were transplanted in
both the wild type and knock down mice, lesion growth increased, inflammation augmented, and
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more angiogenesis was seen in 52 KO mice over wild-type mice; these are characteristic of
defects in decreased PR signaling (39).
Additional studies in human tissues correlate findings from mouse models. Studies
indicate that FKBP52 and AR colocalize in the epithelium of luminal prostate tissue, but
FKBP52 appears absent in stromal cells (11).

FKBP52 expression is decreased in human

endometrial tissues of endometriosis patients (39). Its over-expression in human prostate needle
biopsies of prostate cancer patients has named it a potential biomarker of prostate cancer (40).
Studies at the molecular level also suggest that the immunophilins (particularly FKBP51
and FKBP52) regulate receptors by different mechanisms. They bind Hsp90 by different means;
FKBP52 requires solely the TPR domain for binding, yet FKBP51 requires additional sequences
up and downstream of the TPR domain. Furthermore, FKBP52 binds FK506 without detaching
from a GR complex, yet FKBP51 detaches from the complex when it binds FK506 (41).
Additionally, the Hsp90 client protein (receptor) seems to influence the recruitment of some
immunophilins over others. While FKBP51 and FKBP52 compete with equal preference for
binding to Hsp90 in a purified system with the client PR, they do not appear to have equal
competition in vivo. In a cell-free PR system using reticulocyte lysate (RL), a cell-free extract
containing all the cochaperones and chaperones necessary for receptor assembly, the ratio (in
moles) of Cyp 40: FKBP52: FKBP51 was 10:5:1, yet FKBP51 appeared to associate with PR
complexes up to four times as much as compared to that of FKBP52 and Cyp40 (42).
Furthermore, GR recruits FKBP51 or Cyp40, and ER recruits Cyp40 preferentially (38). This
suggests the possibility that either these immunophilins not only bind Hsp90 but also bind the
receptors directly, or that there are additional, uncharacterized mediators of the individual
receptors, which enforce the preferential recruitment of immunophilins.
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Although FKBP51 and FKBP52 have only a few structural differences, their divergent
functions are still being characterized at the cellular level. FKBP52 can potentiate the action of
GR (12), PR (13), and AR (11) but not ER or MR (12) as transcription factors. FKBP51, on the
other hand, actually causes a decrease in GR binding to glucocorticoids in squirrel monkeys (43).
Riggs et al. showed that FKBP51’s apparent inhibition of GR signaling was actually an
inhibition of FKBP52 signaling through the use of a yeast-based reporter assay. By substituting
FKBP52 for FKBP51 in a transfection involving GR and reporters, a three-fold leftward shift in
potency of a dose response curve for GR was seen. They examined hormone binding affinities
of GR in the presence of FKBP51 or FKBP52 and the rest of the Hsp90 steroid hormone receptor
complex. GR’s hormone binding affinity for deoxycorticosterone (DOC) was up to five times
greater with FKBP52 than with FKBP51. Additionally, in an in vitro study, it appeared that
FKBP51 decreased PR’s response to hormone (12). An increase in progesterone levels seems to
enhance FKBP51 expression; feasibly FKBP51 could serve as a negative regulator of PR-related
pathways (44). FKBP51 is regarded as a repressor of hormone receptor signaling (10). In fact,
FKBP51 often was used as the negative control for AR transcriptional studies with FKBP52
(45).
On the other hand, in the human prostate cancer cell line PC-3, FKBP51 exhibits positive
regulation of AR by increasing its binding affinity for androgen and enhancing the amount of
p23 recruitment to the AR complex.

However, for the purposes of this recent study, the

synthetic hormone concentration reached potentially non-physiological levels of 1nM R1881, a
mutant receptor was studied, and multiple prostate cancer pathways could have been activated
(46).

More research must be conducted to draw any definitive conclusions regarding the
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mechanisms and roles of both FKBP51 and FKBP52 in regulating steroid hormone receptors,
both in pathological and healthy tissues.
One theory regarding immunophilin regulation of receptors was that they could interact
with receptors through a mechanism involving the receptors’ DBDs. Through domain swapping
experiments of ER (which lacks FKBP52 potentiation abilities) and GR, they found that the LBD
of the receptor was responsible for regulation by FKBP52, not the DBD (12).
Other studies focused on the immunophilins themselves to characterize their interactions
and functional alterations in conjunction with steroid hormone receptor complexes. The Smith
lab found that an FKBP52-K354A mutation (a TPR mutation which had previously been found
to disrupt Hsp90 binding) prevents full FKBP52-induced potentiation of AR in a yeast reporter
system, verifying that Hsp90 binding is important for potentiation of the receptor (11). When the
FK1 domains of FKBP51 and FKBP52 were switched, they found that the chimera with an
FKBP52 backbone completely lacked potentiation abilities with GR. However, the chimera with
the FKBP51 backbone gained up to 50% of the potentiation effects of wild-type FKBP52,
suggesting that although the FK1 domain is a crucial component of potentiation, it is not the sole
determinant of FKBP52’s abilities to augment GR signaling (12).
PPIase activity is associated with the FK1 domain, and very early studies of FKBP52
showed that FK506 (which binds FK1) blocked FKBP52’s PPIase activity (47). The Smith
group determined that administration of FK506 prior to addition of hormone effectively
prevented FKBP52’s potentiation of the receptor. However, FK506 is a large drug, so it was
important to verify that steric hindrance was not the reason for potentiation changes. The highly
conserved residues F67 and D68 of the PPIase domain were mutated to form the FD67DV
mutant (12). Previously this mutant was constructed in FKBP51, and it was associated with a
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90% decrease in PPIase activity without affecting association of FKBP51 in PR complexes (41).
When the FKBP52-FD67DV mutation was constructed, potentiation of GR was prevented in a
yeast model (12). However, it only partially decreased AR signaling in a yeast model. Still,
there was still a chance that even this mutation compromised the conformation of FKBP52, so
the mutations F67Y, W90L, and F130Y were constructed, which abrogated PPIase activity
without severely altering the conformation of the PPIase domain itself. These mutations showed
no significant change in wild-type FKBP52-enhanced GR and AR activity in yeast reporter
assays, and the potentiation of AR by FKBP52 was also seen in the 52KO MEF model (45).
Initially, when PPIase activity was deemed critical for receptor potentiation by FKBP52,
researchers searched for prolines in AR, which could serve as potential substrates for PPIase
activity. The AR mutant P723S, found in androgen sensitivity syndrome patients, was one such
mutant of interest. Surprisingly, it actually did not appear to be a substrate for the PPIase
domain but was interesting for another reason: its dependence on FKBP52 for functionality.
Receptor signaling is significantly decreased with this mutant, but signaling is restored in the
presence of FKBP52 (11).
The significance of the PPIase domain was finally determined through random
mutagenesis of FKBP51.

The AR mutant P723S could be exploited for use in a genetic

approach to characterize FKBP52’s functional determinants of potentiation.

A library of

FKBP51 mutants, which had gained FKBP52-like potentiation abilities towards the FKBP52dependent AR P723S, was created. Random mutagenesis of FKBP51 revealed three consistent
mutations, which were associated with FKBP52-like potentiation of AR.

Site-directed

mutagenesis was performed to generate these mutants, and the mutants were examined
individually with wild-type GR and AR in receptor-mediated yeast reporter assays and then with

22

52 KO MEF luciferase assays. When the FKBP51-L119P mutant was assayed in 52 KO MEFs,
it increased receptor potentiation up to five times that of wild type FKBP51. When the converse
mutation was made in FKBP52, the P119L mutant only possessed 50% of the potentiation ability
of wild type FKPB52. The double mutant FKBP51-A116V/L119P exhibited increased AR
signaling up to twenty times higher than wild-type FKBP51, thereby rivaling FKBP52’s
potentiation abilities in both yeast and 52 KO MEFs. These mutations alter the conformation of
a loop, which is suspended above the PPIase pocket in the FK1 domain (45).
Position 119 within the proline-rich loop directly above the PPIase pocket of the FKBPs
differs between FKBP51 and FKBP52. In FKBP52, the amino acid is a proline, and in FKBP51,
it is a leucine. Due to the characteristics of these amino acids, in FKBP52, the loop projects
outward and is more accessible. However, the leucine residue causes FKBP51 to adopt a more
closed conformation of the loop. Nonetheless, the presence of a L119P mutation alone does not
confer full receptor potentiation ability to FKBP51. This suggests that other residues could be
involved in generating FKBP52’s potentiation of receptor. FKBP51/FKBP52 chimera studies in
yeast and 52 KO MEFs revealed that while the FK1 domain seems responsible for the majority
of FKBP52’s potentiation, FK2 and TPR domain interactions may also play a role in this
characteristic potentiation of the AR (45).
Since there have been reports of interactions of FKBP52 with dynein (48), the Smith
group examined GR potentiation by FKBP52 in a dynein-deficient yeast strain, and they found
that FKBP52 exerted similar potentiation of GR signaling independently of a dynein interaction
(12). Originally, it was proposed that the immunophilins PP5, CyP40, and FKBP52 tethered the
receptor to dynein to facilitate retrograde transport of the complex (22), and later it was
suggested that FKBP51, which does not appear to bind dynein, suspends the receptor complex in

23

the cytoplasm until it is an appropriate time for translocation (49). Additionally, FKBP52 has
been implicated in further regulation of receptor compartmentalization by binding tubulin to
prevent its polymerization into microtubules (50). An argument can be made that all the studies
conducted which have demonstrated these interactions have involved purified protein fragments
rather than full length proteins, and none of those studies confirm direct, correlative roles for
FKBP52 in cellular localization in vivo (22, 49-52).
1.5 Β-CATENIN
β-catenin, a 92 kDa protein, is involved in many processes, from signal transduction to
cellular adhesion (53, 54). It is a well-characterized member of various pathways such as the
phosphatidyl inositol-3’-kinase (PI3K)/Akt pathway, insulin growth factor 1 (IGF-1) pathway,
and Wingless/Int (Wnt) pathways, ultimately leading to transcription of targets such as the
protooncogene c-myc, cyclin D, matrix metalloprotease 7 (MMP-7), endothelin 1,
cyclooxygenase 2 (COX-2), survivin, and peroxisome proliferator activated receptor γ (PPARγ).
In many instances, β-catenin acts as a coactivator of transcription. When stimulated by the
secretory glycoprotein Wnt, it interacts with Ternary Complex 4 (TCF4) and Lymphocyte
Enhancement Factor 1 (LEF-1) transcription factors to regulate growth and development genes.
Alternatively, it can associate with AR in response to Wnt stimulation (55-57). β-catenin plays
roles in cell proliferation, apoptosis resistance, cellular migration, carcinogenesis, and
differentiation (58-60). Due to its pervasive nature, this protein has widespread implications for
various types of cancers affecting the ovaries (61), bladder (62), colon (63), breast (64), and
prostate (65).
The Wnt signaling pathway poses several regulatory mechanisms which malfunction in
prostate cancer development. In non-cancerous tissues, β-catenin generally associates with the
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cytoplasmic membrane. Sequestered by the transmembrane epithelial cell protein E-cadherin, βcatenin is unavailable for nuclear translocation and transactivation of transcription factors such
as LEF-1 (66). Instead, it participates in calcium-dependent cellular adhesion mechanisms via
adherens junctions. When β-catenin associates with E-cadherin, the complex actively organizes
and tethers microfilaments in the cell. Meanwhile, E-cadherin’s extracellular portion engages
cadherins of adjacent cells to maintain cellular adhesion (54, 67). β-catenin associates with Ecadherin to modulate intracellular and intercellular signaling events and to regulate
transcriptional events (67, 68). Any unbound β-catenin is generally tagged for destruction by the
degradation complex, which consists of Glycogen Synthase Kinase 3 β (GSK3β), the tumor
suppressor Adenomatous polyposis coli (APC), the scaffolding protein axin, and casein kinase 1
(69).
The classic Wnt pathway states that Wnt activation of the Frizzled receptor deactivates
the degradation complex member GSK3β, thereby enabling cytoplasmic β-catenin to evade
ubiquitination due to its de-phosphorylated status.

Wnt induction of the receptor allows

translocation of free β-catenin to the nucleus for regulation of gene expression (70). Figure 1.7
shows a summary of the Wnt pathway.
In prostate cancer, β-catenin participates in cytoplasmic and nuclear events due to Wnt
induction.

Wnt inhibition is decreased and Wnt expression increases in prostate cancer.

Expression of the natural Wnt inhibitor, Wnt inhibitory factor 1 (WIF1), is often decreased in
prostate cancer cells (71), and in particular, expression of the β-catenin stabilizing factors Wnt 1,
2, and 5a are up-regulated in these cells (72).
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Figure 1.7: Wnt Pathway Signaling
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Figure 1.7: Wnt Pathway Signaling

In the absence or presence of Wnt protein, β-catenin associates with E-cadherin near the
cytoplasmic membrane and helps to tether E-cadherin to the actin cytoskeleton. Wnt signaling is
initiated when Wnt binds the Frizzled receptor, leading to the recruitment of Disheveled protein
to the membrane. Therefore, GSK3β does not activate the destruction complex, and cytoplasmic
β-catenin accumulates and is available for nuclear roles as well. In the absence of Wnt, any free
cytoplasmic β-catenin is tagged for destruction by the GSK3β/APC/axin complex. This is an
adaptation of Figure 1 of Journal of Biomedicine and Biotechnoogy. 2011; 2011: 567305.
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When LNCaP prostate cancer cells are treated with conditioned media with Wnt 3a, the
result is cell growth and colony formation, which is associated with increased prostate specific
antigen (PSA) transcription regardless of AR ligand presence or absence (73, 74). Androgenindependent, invasive PC-3 and DU145 prostate cancer cell lines exhibit higher amounts of
Wnt/β-catenin signaling than androgen-dependent LNCaP cells or normal prostate cells (75).
In prostate cancer, β-catenin dissociates from E-cadherin due to debilitation of members
of the destruction complex. Phosphorylation-defective β-catenin mutants are found in a small
number of prostate cancer patient tissues (76), but they are not found in the major prostate cancer
cell lines (77).

APC, another member of the degradation complex for β Catenin, can be

deactivated by post-translational modifications. By deactivating β-catenin’s nuclear antagonist,
β-catenin is thereby available and capable of regulating transcription (78). β-catenin expression
is up-regulated in prostate cancer cells, and a greater percentage of β-catenin is found in the
nucleus in cancerous cells as compared to normal cells (72). In metastatic prostate cancers, Ecadherin expression is decreased, resulting in a greater proportion of cytoplasmic and nuclear βcatenins (79). Thus, the destruction of E-cadherin promotes β-catenin signaling via the Wnt
pathway.
Increased transcription of AR-target genes is a hallmark of prostate cancer (80). One
study suggests that β-catenin modulates AR’s requirement for ligand binding, thereby inducing
AR hypersensitivity to circulating androgens (81).

Thus, β-catenin could play a role in

transitioning prostate tissues from a hormone-dependent to a hormone refractory stage when AR
is constitutively activated, regardless of concentration of circulating hormone. Wnt signaling
involving β-catenin is implicated in two main areas of androgen receptor (AR) regulation. In the
direct pathway, β-catenin is a co-activator of AR-mediated transcription (82). In the indirect
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pathways, β-catenin participates in the regulation of AR signaling via its interaction with other
pathways. For example, Wnt stimulation deactivates GSK-3β, resulting in a wide range of
effects on AR in its hyperphosphorylated state. However, in these pathways β-catenin itself
never contacts the receptor directly to change its phosphorylation status (83, 84). Studies of
AR(+) LNCaP and AR(-) PC3 cells using time-course fractionation and localization studies
suggest that AR participates in transporting β-catenin to the nucleus in response to the hormone
agonist R1881, and that β-catenin is present in the complex even at the point of AR binding to
hormone response elements (85).
In 2003, the Gelmann lab characterized some of the critical residues of AR, which
participate in binding to β-catenin. In these studies, β-catenin bound the receptor near the AF-2
domain of the LBD in experiments employing a mammalian two-hybrid binding model. While
β-catenin was able to bind the receptor in the absence of ligand, binding increased tremendously
in the presence of the hormone agonist R1881. When a K720A mutation was made in helix 3 of
AR, the binding of β-catenin was disrupted. However, the mutation simultaneously decreased
the binding affinity of the NTD:LBD interaction of the receptor and additionally decreased the
incidence of the P160 coactivator transcriptional mediators/intermediary factor 2 (TIF-2)’s
binding to the receptor. This suggests that, rather than being the main determinant of β-catenin
binding, this mutation may merely compromise the conformation of AR. Additionally, several
amino acids at positions 891-902 on helix 12 of AR were mutated, resulting in a wide range of
effects on hormone binding as well as alterations in binding to β-catenin, TIF-2, and
transactivation of the receptor. Particularly, they found that a mutation of AR at residue E893A
of helix 12 caused a huge decrease in binding to β-catenin, a smaller decrease in binding to the
NTD of the receptor, and only a minor decrease in binding to TIF-2 (81).
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Labs have also attempted to determine critical determinants of β-catenin binding to AR,
but there was less success at pinpointing exact residues. The armadillo repeats of β-catenin
appear to be crucial for its interactions with AR, as found through yeast two-hybrid studies (82)
as well as glutathione-S-transferase (GST) pull-down assays (85). GST-pull-down assays by the
Gelmann lab showed that androgen receptor LBD pull-down utilizing full-length β-catenin
protein as bait was strengthened with R1881 addition. When a fragment of β-catenin’s Cterminal domain was used containing armadillo repeats 8-12, β-catenin bound AR LBD
regardless of hormone concentration. When a N-terminal β-catenin fragment comprised of
repeats 1-3 was used, very little AR LBD pulled down, but R1881 addition increased the
interactions. Because β-catenin has five NR boxes, they theorized that maybe the interaction
motifs in helices 1, 3, 7, 10, and 12 were responsible for the β-catenin/AR interaction, but
individual mutations to these motifs did not affect AR binding. To see if β-catenin’s interaction
with AR could be prevented, the protein inhibitor to β-catenin and TCF-4 (ICAT), which
competitively binds β-catenin at the armadillo repeats used to bind TCF-4, was employed. It
successfully disrupted β-catenin/AR interactions as well (81). This could suggest similarities of
binding sites between AR and TCF-4. More studies are needed to characterize β-catenin/AR
interactions.
1.6 PROSTATE CANCER
Cancer is undeniably one of the most challenging universal health problems. One in two
men and one in three women will face cancer in their lives. The number of cancer survivors
increases steadily due to better medical care as well as increased life expectancy. In a survey on
January 1, 2012, 13.7 million Americans reported a history of cancer, and the three most
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prevalent cancers among the male population were melanoma (7%), colorectal (9%), and
prostate (43%) (86).
Prostate cancer is an undeniable concern of many men in the US. According to the
National Cancer Institute (NCI), one out of every six men in the US will develop prostate cancer
(87). Prostate cancer is the most commonly diagnosed tumor and the second leading cause of
cancer-related deaths in the US (88). It is the second most common cancer in men, second to
skin cancer. The American Cancer Society (ACS) stated that in 2012, it was predicted that
241,740 people would be diagnosed with prostate cancer, and approximately 28,170 people will
die due to the disease (89). In the 2009 Surveillance Epidemiology and End Results study
sponsored by the NCI, it was determined that the median age of prostate cancer patients is 67,
and the median age of death is 80 (87).
There are virtually no symptoms in early stage prostate cancer, but some patients develop
pre-cancerous conditions such as benign prostatic hyperplasia (BPH) and prostatic intraepithelial
neoplasia (PIN). In BPH, a natural consequence of age, the prostate tissue near the urethra
continues to grow, restricting the flow of urine and semen. In PIN, prostate cells begin to appear
abnormal as sampled but do not express biomarkers of cancer or tumor formation (89).
Prostate cancer is commonly diagnosed through the biopsy Gleason score, the extent of
the primary tumor via the digital rectal exam, and serum PSA levels. Risk of reoccurrence is
calculated based on the overall results of these three tests (88). Although PSA screening has
been a standard recommendation for older men and indeed resulted in more frequent diagnoses
of prostate cancer since its introduction in the 1990s (90), it has been questioned as a valid
measurement of cancer burden when used alone. According to the ACS, “At this time, there are
insufficient data to recommend for or against routine testing for early prostate cancer detection
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with the PSA test.” The risk factors in prostate cancer are age, race, and family history. It is
possible to have prostate cancer and have no symptoms, but when a patient presents at the
advanced stages of disease, the chief complaints are painful or discontinuous urination and the
presence of blood in urine (91). Additionally, 68% of advanced prostate cancer patients will
experience bone metastasis (86).
Castration-resistant prostate cancer (CRPC), also referred to as androgen-independent
prostate cancer, is cancer that continues to develop despite low levels of serum testosterone as
seen in castration. Recently, scientists have determined that the term androgen-independent is a
misnomer; cancer patients who have CRPC are actually hypersensitive to trace levels of
hormone (92). Generally, CRPC emerges in 10-20% of prostate cancer patients approximately
five years after beginning prostate cancer treatment (93). When treatment involves androgen
deprivation therapy, CRPC progression occurs between 1 to 2 years later, with a median survival
rate of 1-2 years following onset of CRPC. CRPC can progress in spite of castration or hormone
therapy into a stage termed hormone refractory prostate cancer (HRPC) in which it is no longer
responsive to any types of hormone therapy (89). This state is possibly due to AR amplification,
AR point mutations, AR coactivator overexpression, AR repressor underexpression, hormone
independent splice variants, epigenetic alterations, and increased adrenal or intratumoral
androgen production (94, 95). In CRPC and HRPC, PSA levels typically increase, indicating
that AR signaling pathways are activated (94), but in some cases, the prostate cancer progresses
even in the absence of increased serum PSA (96).
1.7 PROSTATE CANCER TREATMENTS
The manner by which prostate cancer is treated depends on the age of the patient, the
stage of the cancer, and the desires of the informed patient. In less advanced cases of prostate
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cancer, 57% of patients 65 and younger choose radical prostatectomy. In patients 65 to 74, 33%
are treated in this manner, and 42% are treated by radiation. Advanced stage and metastatic
patients are treated by androgen deprivation therapy (ADT), radiation therapy, bone-metastasis
therapy, or a combination of treatments. The most common side effect of ADT treatment is
sexual difficulty, present in 80% of patients (86).
1.7.1 Conventional Prostate Cancer Treatments
Early stage prostate cancer patients typically are treated through radiation or surgery. In
radiation treatments, either external beam radiation exposure is used or radioactive seeds are
implanted into the prostate. Alternatively, the prostate can be removed (91). Both treatments
appear to have similar efficacy. Side effects of surgery are incontinence, lymphedema,
impotence, and decreased fertility. Side effects of radiation treatment are bowel problems,
incontinence, and fatigue (89).
Late stage, metastatic prostate cancer patients are treated through androgen deprivation
therapy. Hormone therapy has been used to treat these patients for greater than 70 years, but it is
still a controversial therapy (94). ADT’s goal is to reduce the circulating DHT concentration to
20 ng/dl or less, which is about 80% of many of the CRPC patients’ circulating hormone
concentration (97). ADT can entail castration (orchiectomy) and/or the use of therapeutics such
as CYP17 inhibitors, luteinizing hormone releasing hormone (LHRH) agonists or antagonists, or
anti-androgens (89, 97). The CYP17 inhibitors such as ketoconozole and abiraterone prevent the
conversion of C21 steroids into C19 adrenal androgens. LHRH agonists and antagonists
interfere with the production of DHT at a more preliminary level of the pituitary-testicular axis
(97). The problem with LHRH agonists is that initially, they cause a surge of testosterone as
they stimulate leutenizing hormone (LH) and follicle stimulating hormone (FSH), but within 4-6
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weeks, the LHRH receptors are down-regulated in the presence of excess hormone, and then
testosterone will actually decrease to castration levels (91). LHRH antagonists prevent the
downstream production of testosterone by blocking the production of LH and FSH (89). LHRH
agonists and antagonists do not prevent production of DHT through the adrenal gland, which is
responsible for 5-10% of circulating androgen.
Non-steroidal anti-androgens were created to address this problem (94). Non-steroidal
anti androgens such as Bicalutamide (Casodex; Astra Zeneca, London, U.K.) and Flutamide
(Eulexin; Schering, Kennelworth, N.J.) compete with hormone in binding the AR LBD
selectively but do not induce wild type (wt) AR-mediated transcription (98). However, when AR
is over-expressed or a mutant receptor such as T877A or W741L/W741C is present as seen in
long-term ADT patients, many anti-androgens can agonize AR activity rather than antagonize it.
In the case of over-expressed AR, experiments showed differential recruitment of co-activators,
which are associated with agonist activity (97, 98). In LNCaP cells with the AR-activating
mutation T868A, Bicalutamide did not show agonist properties to the mutant AR like other antiandrogen drugs (99). Bicalutamide is the commonly employed anti-androgen drug used in
combination with LHRH agonists and antagonists in ADT therapy for treatment of patients with
metastatic prostate cancer (94, 98). Although it was utilized in monotherapy and was initially
lauded for its equal efficacy to castration without the side effects (100), Bicalutamide blocks AR
activity in the pituitary and prostate, and LHRH release often ensues to increase the production
of testosterone (98), so it is most effective in conjunction with LHRH inhibitors.
Enzalutamide (Xtandi; Astellas Pharma, US, Northbrook, I.L.) is in the next generation
of nonsteroidal anti-androgens, and unlike drugs like Bicalutamide and Flutamide, it does not
have agonist properties in the presence of overexpressed AR. Additionally, Enzalutamide also
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blocks AR translocation (94). The Food and Drug Administration has now approved
Enzalutamide to treat prostate cancer patients with metastatic disease who have completed
treatement with the anti-mitotic drug Docetaxel (Sandoz; Princeton, NJ).
When a patient ceases to respond to one form of ADT, often a combination of
orchiectomy and LHRH analogs/anti androgens are used, commonly referred to as combined
androgen blockade (89). The primary side effects of ADT are decreased sex drive, menopausal
symptoms, osteoporosis, and increased risk of hormone associated disease (86).
ADT-resistant patients can undergo treatments of chemotherapy, vaccines, and
biophosphonates. In chemotherapy, drugs such Docetaxel and the DNA intercolator
Doxorubicin (Pfizer; New York, N.Y.), to prevent cell division, are often employed. Side effects
include hair loss, mouth sores, appetite suppression, nausea, and heart trouble. The vaccine
Sipuleucel-T (Provenge; Dendrion Corrporation, Seattle, W.A.) entails the removal of white
blood cells from the patient, exposure to prostatic acid phosphatase, and the intravenous delivery
of the activated T-cells in a three part series to boost immune response to cancerous cells.
Biophosphonates can be used to alleviate pain in patients with bone metastasis (89).
1.7.2 Novel Approaches in Prostate Cancer Treatments
There are currently several novel approaches to the treatment of prostate cancer. Some of
these include novel AR-targeting drugs which target novel surfaces of the LBD (101) besides the
area of helix 12 where ligand directly binds, as well as the N-terminal inhibitors which block
transactivation of the receptor. Others include Hsp inhibitors which affect the stability of AR,
histone deacetylase (HDAC) inhibitors which affect the transcription of AR and AR target genes,
mammalian target of rapomycin (mTOR) inhibitors which prevent AR ligand-independent
activation via the PI3K/Akt/mTOR pathway, and Src-kinase inhibitors which block signal
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transduction of several cell surface receptors which are often active in CRPC patients (97). Two
of these treatments are of particular interest to this project, the AR BF3-surface inhibitors and
Hsp90 inhibitors.
Androgen Receptor BF-3 Surface Inhibitors
In 2007, the Fletterick group identified the BF3 surface on the AR ligand binding
domain.

Compound screenings of drugs that targeted this hydrophobic surface effectively

prevented the binding of AR coactivators SRC2, SRC3, and ARA70 and resulted in decreased
receptor signaling. X-ray diffraction images of the compounds Triac and flufenamic acid with
AR revealed that rather than binding the coactivator binding surface AF-2 as initially expected,
these compounds bound the BF-3 surface and altered the orientation of AF-2. The BF-3 cleft is
located at the intersection of helix 9, the loop connecting helix 3 to helix 5, and helix 1. BF-3
surface inhibitors tremendously decrease receptor potentiation and represent a novel approach to
receptor targeting as they may serve as an allosteric control to coactivator binding (101).
Our lab had characterizied many of the same BF-3 surface residues on AR that the
Fletterick lab had targeted using their molecule. From our studies, this AR BF-3 surface was
implicated as the putative binding site for the immunophilin and cochaperone protein FKBP52.
Mutations to these residues were associated with a greater sensitivity to FKBP52 regulation of
the receptor (102, 103). Mutations to BF3 surface residues are seen in patients with androgen
insensitivity syndrome (104-107) and prostate cancer (105). Our lab developed a novel
compound, MJC13, based on modifications of H7 parent compound, which is similar in structure
to fenamic acid derivatives that the Fletterick lab developed. This drug binds to the AR LBD
and likely binds the BF-3 surface of AR as predicted by in –silico docking simulations.
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Hsp90 Inhibitors
For several years, scientists have theorized that Hsp90 could be a good therapeutic target
for cancer treatments.

Oncogenic proteins are overexpressed at such rapid rates that they

become misfolded and unstable in cancerous conditions. These proteins are dependent on Hsp90
for functionality and existence. Indeed, it has even been asserted that “cancer cells are addicted
to Hsp90” because without them, the misfolded oncogenes would be degraded and the cancerous
cell could not propagate. The majority of Hsp90 inhibitors bind at the N-terminus, and recently
designed ones now bind to the C-terminus (29).
In 1999, 17-N-Allylamino-17-demethoxygeldanamycin (17AAG) was the first Hsp90
inhibitor to reach Phase III clinical trials (108). Over 23 Hsp90 N-terminal inhibitors are in
clinical trials presently (108). Hsp90 inhibitors seem to accrue more rapidly in cancer cells over
non-cancerous cells (109, 110), and the inhibitors appear to be more potent towards cancer cells
(111). Hsp90 has been used in conjunction with other drugs to help increase their efficacy. For
example, 17-AAG was used effectively with Trastuzumab (Herceptin; Genentech, San
Francisco, CA) in Phase II Human Epidermal Growth Factor Receptor 2 (HER2) + breast cancer
clinical trials to the benefit of 57% of the patients (112). During Phase I and II trials of multiple
myeloma, 17AAG was used with the proteasome inhibitor Bortezomib (Velcade; Millenium
Pharmaceuticals, Cambridge, M.A.), and resistance to bortezomib was in some cases, overcome
(113). This combinatorial approach actually induced apoptosis, and it is postulated that this
happened because protein degradation was blocked and misfolded proteins were accumulating
(114).
While Hsp90 inhibition was effective in treating several cancers in clinical trials, it was
not effective in helping patients with CRPC. Cancer researchers originally thought that the
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inhibitor would bring relief to CRPC patients since the androgen receptor is an Hsp90 client
protein and the androgen receptor is often still active in castrate resistant prostate cancer.
However, treatment with the Hsp90 inhibitor IPI-504 helped 25% of patients as evinced by a
PSA decrease of nearly half, but in patients with bone metastasis, no change was seen (115).
When 17AAG was used in another prostate cancer Phase II trial, there was no benefit to the
patient (116).
Critics of these drugs have stated that while pro-cancer proteins are obvious targets of
this therapy, other client proteins are also impacted. For example, Hsp90 inhibitor treatment in
one experiment actually promoted transformation due to the loss of tumor suppressor Interferon
Regulatory Factor 1 (IRF1). In the absence of IRF1 and the presence of a Ras mutation,
transformation occurred (117). Additionally, the use of Hsp90 N-terminal inhibitors can prolong
heat shock protein response. This is a problem in cancer treatment because Hsp90 disassembles
transcriptionally active HSF-1 trimers. In a Xenopus laevis oocyte model, treatment with the
Hsp90 inhibitor geldanamycin prolonged heat shock response (118).

HSF-1 trimers actively

promote oncogenesis (118, 119). Also, drug delivery and dosing must be carefully administered
or results will be poor. In the case of one Phase II metastatic melanoma trial involving 17AAG,
no benefit was shown to the patients, but further investigation of biopsies showed that Hsp90
was not effectively being inhibited (120).
Because of the heat shock response induced by N-terminal inhibitors, the novobiocin
derived C-terminal Hsp90 inhibitors have been developed. One drug of promise is KU135. This
drug was more effective in promoting apoptosis of Jurkat T cell leukemia lymphocytes than
17AAG (121).
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Though these drugs administered alone are less effective at treating prostate cancer than
other cancers, it is feasible that combinations of Hsp90 inhibitors and other drugs might increase
their efficacy in a prostate cancer setting.
1.8 CURRENT RESEARCH FOCUS
In the present study, I demonstrate that β-catenin and FKBP52 synergistically potentiate
AR signaling in the 52 KO MEF and 22RV1 prostate cancer cell lines. AR signaling increases
thirty-fold over vector when β-catenin and FKBP52 are co-transfected with AR in a luciferase
assay of 52 KO MEF cell lysates. β-catenin and FKBP52 can interact directly in vitro in the
absence of other proteins, as demonstrated by a GST-pull down assay. As assessed in 52 KO
MEFs, an FKBP52 K354A mutation, which disrupts binding to Hsp90, does not abrogate βcatenin and FKBP52 synergism of AR. FKBP52 does not require PPIase activity to produce AR
synergism with β-catenin. However, FKBP52’s proline-rich loop overhanging the PPIase pocket
of FKBP52 is a critical structural determinant of synergism. Synergism is DNA sequencespecific, indicating that the impacts of synergism occur at the transcriptional level. The ARspecific inhibitor MJC13 effectively abrogates synergism with a half maximal inhibitory
concentration (IC50) of 1 μM in the 52 KO MEF model. MJC13 inhibition of receptor is not
enhanced with the addition of Bicalutamide or the Hsp90 inhibitors KU174 and 17AAG. In
studies comparing FKBP52 knock down 22RV1 (52 KD 22RV1) cells against wt 22RV1 control
cells, β-catenin transfection only doubles AR transcriptional activity in the presence of minimal
FKBP52. However, when FKPB52 is present as in the control cells, β-catenin transfection
increases AR transfection activity one hundred fold over vector. This proves the importance of
FKBP52 as a requirement for robust enhancement of AR signaling due to β-catenin.
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1.9 HYPOTHESIS
FKBP52 and β-catenin interact directly in a synergistic manner to influence
transcriptional events of the androgen receptor.
1.10 DISSERTATION GOALS
The overall goals of this work are to highlight the previously undocumented interactions
of β-catenin and FKBP52 as they synergistically regulate AR in the 52 KO MEF model system,
to block the synergism, and then to determine the relevance of this synergism in a prostate cancer
cell line. An attempt has been made to understand this regulation of AR by addressing the
following questions:
1.

What are the important components of β-catenin and FKBP52 synergism?

2. Can we prevent FKBP52/ β-catenin synergism with inhibitors such as AR BF3
surface inhibitors, androgen antagonists, Hsp90 inhibitors, or combinations thereof?
3.

Does FKBP52/ β-catenin synergism exist in prostate cancer cells?

In addressing these questions, we will elucidate some of the key elements by which the
AR regulatory proteins β-catenin and FKBP52 work in tandem to coactivate transcription, and by
therapeutically targeting this interaction, we offer an alternative method to prevent progression
of prostate cancer. In testing our hypothesis, we not only gain a more complete understanding of
the androgen receptor complex, but we present a novel therapeutic target for prostate cancer. The
FKBP52/ β-catenin /SHR complex may be an effective target exploitable in treatment of other
pathologies involving steroid hormone receptors.
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Chapter 2: Elucidation of the Important Components of β-catenin and
FKBP52 Synergism
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2.1 RATIONALE
Prior to the studies conducted here, β-catenin and FKBP52 had been studied separately as
positive regulators of androgen receptor complex signaling pathways (11, 57, 81, 82, 122), but
no studies have suggested that the proteins work in concert to regulate androgen receptor
signaling. Initially, our studies in yeast suggested that AR BF3 surface mutations cause FKBP52
dependency (103), fenamic acid inhibitors which contact the AR BF3 surface at those same
residues implicated for FKBP52 potentiation of AR prevent full AR signaling (101, 103), and
because FKBP52 differentially regulated the steroid hormone family while in the presence of
Hsp90 suggested direct contact of FKBP52 to AR (11-13), we believed that FKBP52 contacted
AR at the BF3 surface. The Fletterick lab was analyzing data which showed that the BF3 surface
of Liver Receptor Homologue-1 (LRH-1) was implicated as the binding site for β-catenin (123),
and it was possible that β-catenin regulated the BF3 surface of AR, as well. No crystal structures
had been generated for AR complexed with either β-catenin or FKBP52. Thus, we wished to
investigate whether FKBP52 and β-catenin could compete for binding or work in tandem to
regulate AR through the BF3 surface.
Our initial hypothesis was that FKBP52 and β-catenin would compete for binding to the
AR BF3 surface, and that co-transfection of both proteins with AR would result in a masking
effect by which the stronger binding protein would mask the effect of the other. To investigate
this hypothesis, we would initially perform an AR-mediated reporter assay in mammalian cells to
discriminate differences in AR reporter gene expression when FKBP52 and β-catenin were cotransfected (both individually and together) with AR and reporters. Following this initial assay,
a pull-down assay was performed with FKBP52 and β-catenin, mutations were performed in
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FKBP52 to characterize the components of regulation, and different AR promoters were utilized
in AR mediated reporter assays to determine important components of regulation.
2.2 MATERIALS AND METHODS
2.2.1 X-Ray Crystallography and Superposition of AR LBD over LRH-1 LBD
The crystal structure of β-catenin armadillo repeats (residues 138-663) complexed with
LRH-1 hinge region (residues 191-541) was solved by the Fletterick laboratory as referenced
(123). Briefly, fragments of β-catenin were subcloned into pCDF-2 Ek (EMD Millipore,
Madison, WI) and fragments of LRH-1 were subcloned into pET32 Xa/LIC (EMD Millipore,
Madison, WI), and the plasmids were transformed and grown into BL21Star (DE3) cells
(Invitrogen, Carlsbad, CA). Batch purification was performed using Ni-nitrilotriacetate beads
(Qiagen, USA) and secondary purification was performed with Superdex 200 10/30 (GE
Healthcare, Sweeden). Proteins were concentrated, crystallized in 20mM Tris HCl (pH8.5) with
40% PEG200. Diffraction data was obtained at the Lawrence Berkeley National Laboratory
(Beamline 8.3.1) (UCSF, CA), and molecular replacement was performed using Phaser in
Collaborative Computation Project 4 Suite (CCP4) (Warrington, UK).
Superposition of the AR ligand binding domain with a BF3 binding molecule (Protein
database 2PIT) over LRH-1 hinge LBD was performed with Topp in CCP4. The crystal
structures and space fill models were generated from this superposition using CCP4.
2.2.2 Gal-4tk-Luc Assays in HeLa Cells
HeLa cells were maintained in 5% CO2 in HyClone Minimal Essential Media/Eagles
Essential Salt Solution with 2 mM L-glutamine (Thermal Scientific, Logan, UT) supplemented
with 10% Charcoal/Dextran Treated Fetal Bovine Serum (HyClone, Logan, UT) 24 hours prior
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to the transfection. For transfections, cells were plated at 2.5 x105 cells/well for overnight
incubation. 200 ng of the GAL4-responsive luciferase plasmid, 10 ng of β-actin β-galactosidase
control plasmid, 10 ng of the GAL-AR expression vector or vector control (28), and 100 ng of βcatenin in pCI Neo (Addgene, Inc, Cambridge, MA) or empty pCI Neo vector control (Promega,
Madison WI) were mixed with 0.5µL of Transfectin Lipid Transfection Reagent (Bio
Rad, Hercules, CA) for 24 hours. Cells were collected and lysed in 100 µL of 100mM TrisHCl
(pH7.5) with 0.1% Triton-X-100. Luciferase and β-gal were quantified using the luciferase
assay system (Promega, Madison, WI) and the Gal Screen System (Applied Biosystems,
Bedford, MA) according to manufacturers’ specifications.
2.2.3 Receptor-Mediated Reporter Assays in 52 Knockout MEFs
For assays, immortalized 52 KO MEF cells, generated previously from FKBP52
knockout mice (13), were cultured in 5% CO2 in HyClone Minimal Essential Media/Eagles
Essential Salt Solution with 2 mM L-glutamine (Thermal Scientific, Logan, UT) supplemented
with 10% Charcoal/Dextran Treated Fetal Bovine Serum (FBS) (HyClone, Logan, UT) 24 hours
prior to the transfection. Cells were plated at a concentration of 2 x106 cells/well in 6-well plates
at approximately 80% confluence. They were transfected in duplicates using lipofectamine 2000
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.

Transfections were

performed for 5 hours at a DNA to lipofectamine ratio of 1:3 in MEM-EBSS lacking FBS. The
transfection cocktail was mixed as follows: 50 ng of the pCMVβ β-galactosidase normalizing
reporter plasmid (Clonetech, Mountain view, CA), 400 ng of either a pT81 (American Type
Culture Collection, Manassas, VA) plasmid expressing firefly luciferase reporter driven by the
androgen-dependent Probasin promoter, the androgen-responsive mouse mamory tumor virus
(MMTV) promoter, or the PSA promoter. 800 ng of the pCI-Neo plasmid (Promega, Madison
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WI) expressing human AR, and 800 ng of the pCI-Neo plasmid expressing FKBP52, FKBP51,
FKBP51 or FKBP52 mutants, and/or 800 ng of pCMV-Sport6 plasmid (Open Biosystems, USA)
expressing β-catenin, with 800 to 1600 ng of pCI-Neo plasmid containing normalizing vector.
The PSA promoter and enhancer were previously subcloned into the pGL-2 basic (Promega,
Madison, WI) firefly luciferase promoter; this plasmid was kindly donated by Marianne
Sadar (124).
The S33A degradation resistant mutant form of β-catenin was constructed using forward
and reverse primers as well as the Quick Change II Site Directed Mutagenesis Kit (Cell
Signaling Technologies, USA) in a polymerase chain reaction (PCR) of the pCMV-Sport 6 βcatenin plasmid according to manufacturer’s protocols. The FKBP51 and FKBP52 mutants were
constructed using forward and reverse primers as well as the Quick Change II Site Directed
Mutagenesis Kit (Cell Signaling Technologies, USA) in a PCR of the pCI-Neo plasmid
expressing FKBP51 or FKBP52 according to manufacturer’s protocols.
Twenty-four to thirty hours after transfection, medium was replaced with medium
containing 10 pM DHT (or a range of doses, as appropriate). After approximately sixteen hours
of incubation with hormone, cells in each well were lysed using 100µL mammalian protein
extraction

reagent

(M-PER)

(Pierce,

Rockford,

IL)

supplemented

with

Complete

ethylenediaminetetraacetic acid (EDTA)-free Mini Protease Inhibitor (Roche, Manheim,
Germany) and spun using a microcentrifuge to remove impurities. Luciferase expression was
quantified by mixing 40 µL cell lysate with 100 µL of luciferase assay reagent (Promega,
Madison, WI) in a single well for each sample on a 96 well plate. β-galactosidase expression
was quantified by adding 20 µL cell lysate with 100 µL of Gal Screen Reagent (Tropix, Bedford,
MA). The 96-well plates were incubated at room temperature (incubation time was
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approximately 5 minutes for the luciferase assay and 2 hours for the β-galactosidase assay),
followed by quantification of luminescence by a microplate luminometer (Luminoskan Ascent,
Thermo Labsystems).

Luminescence was measured in Relative Light Units (RLU). The

transfection-efficiency normalized levels of reporter expression (luciferase RLU/ β-galactosidase
RLU) were reported in graphical form using Graphpad Prism software and were all normalized
to 100% expression.
The data shown in the composite promoter graph represent five independent experiments
(plus SDs [error bars]) averaged. The data are plotted as the fold induction of AR in the presence
of FKBP52 and β-catenin co-expression, as compared to AR activity in the presence of empty
vector alone.
All data was represented as the mean (+/- standard deviation) of at least two separate
samples, and figures are composite graphs representing data from at least three independent
experiments.
2.2.4 Western Blot of Cellular Lysates
To confirm equivalent expression of each protein, Western immunoblots were performed
using the prepared lysates from assays as described above. Duplicate samples were combined.
After quantifying protein concentrations of each lysate, an equivalent amount of protein was
loaded for each sample lane on Criterion gels (BioRad, Hercules, CA), and proteins were
separated by electrophoresis. The proteins were then transferred from the gels to Immobilon
Polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, ME), and the membranes were
blotted for protein expression.

The following mouse monoclonal antibodies were used as

primary antibodies: anti-FKBP51 FF1 (epitope in FK1 domain), anti-FKBP52 Hi52D (epitope
in FK1 domain), and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Biodesign
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International, Saco, ME) as a loading control. The following rabbit polyclonal antibodies were
used as primary antibodies: anti-AR (N-20 Santa Cruz, Santa Cruz, CA) and anti-β-catenin
(AbCam, Cambridge, MA).

Anti-rabbit and anti-mouse secondary antibodies (Southern

Biotechnology, Birmingham, AL) were used, and the ImmunStar Alkaline Phosphatase Substrate
(BioRad, Hercules, CA) was applied prior to exposing to X-ray films for development and
detection of antibodies.
2.2.5 In vitro Binding Studies
For the assessment of the ability of β-catenin to bind FKBP52 in vitro, a GST pull-down
assay was performed. 20 µL Glutathione-Sepharose 4B (GE Healthcare, Sweeden) beads were
added to microcentrifuge tubes, samples were centrifuged at at 4°C, and supernatant was
removed. Beads were washed in ice-cold Binding Buffer [50mM HEPES (pH 7.4), 50mM KCl,
10mM MgCl2, 0.01% Tween 20, 1 mM DTT] supplemented with EDTA free, Halt™ protease
inhibitor cocktail (Pierce, Rockford, IL) and resuspended in 400µL of the Binding Buffer. GSTTagged β-catenin (Millipore, Tamecula, CA) was added to two microcentrifuge tubes, and tubes
were inverted using the Hula Mixer (Invitrogen, Oslo, Norway) for 1.5 hours at 4°C. All tubes
were centrifuged at 4°C and supernatant was removed. Next, ice-cold Wash Buffer [50mM
HEPES (pH 7.4), 50mM KCl, 10mM MgCl2, 0.08% Tween 20, 1 mM DTT] supplemented with
EDTA free, Halt™ protease inhibitor cocktail (Pierce, Rockford, IL) was employed for three
washes.

Samples were resuspended in 400µL Binding Buffer.

An equimolar amount of

bacterial batch-purified FKPB52 protein as β-catenin was added to two tubes: one containing
GST with β-catenin and one with solely GST. All samples were inverted using the Hula Mixer
(Invitrogen) for 1.5 hours at 4°C.

Samples were centrifuged at 4°C and supernatant was

removed. Samples were washed in Wash Buffer three times, and supernatant was removed. 15
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µL of BME/4xSDS solution were added to each sample, including input samples of FKBP52 and
β-catenin protein, and all samples were placed the heat block to denature at 95°C for five
minutes.

Samples were loaded onto Criterion gels (BioRad, Hercules, CA), and proteins

separated by electrophoresis. The proteins were transferred from the gels to Immobilon PVDF
membranes (Millipore, Bedford, ME), and the membranes were blotted for protein expression.
The following primary antibodies were used to detect proteins of interest: Rabbit polyclonal to βcatenin (Millipore, Tamecula, CA) and mouse monoclonal anti-FKBP52 Hi52d (epitope in FK1
domain).

Anti-rabbit and anti-mouse secondary antibodies (Southern Biotechnology,

Birmingham, AL) were used in detection of primary antibodies. The ImmunStar Alkaline
Phosphatase Substrate (BioRad, Hercules, CA) was applied prior to exposing to X-ray films for
development and detection of antibodies.
2.3 RESULTS
2.3.1 Identification of a Putative Interaction Surface between the Region Surrounding AR’s
AF-2 Surface and the β-catenin Armadillo Repeats
An X-ray crystallographic structure of the β-catenin armadillo repeats complexed with
the LRH-1 hinge LBD suggests interaction between the third through seventh armadillo repeats
of β-catenin and a region encompassing the AF-2 and BF-3 surfaces of the receptor’s ligand
binding domain (123). Mammalian-2-hybrid studies have suggested that β-catenin binds the
androgen receptor similarly near its AF-2 surface (81). Other studies employing yeast twohybrid studies (82) as well as GST pull-down assays (85) have shown that β-catenin’s armadillo
repeats are crucial for interactions with AR. GST-pull-down assays revealed that β-catenin
mutants Y306A, K345A, and W383A do not bind to LRH-1 or AR well. In these studies,
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binding to AR or LRH-1 was only possible with the wild-type β-catenin protein; the study
suggests that β-catenin interacts AR similarly to its association with LRH-1 (123). These results
established commonalities between the LRH-1 and AR interfaces with β-catenin.
Figure 2.1 presents the superposition of the interaction of β-catenin armadillo repeats
with the LRH-1 hinge LBD (Protein Database 3TX1) superposed with the AR LBD with the [4(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]-acetic acid molecule bound (Protein Database
2PIT). The LRH-1/ β-catenin interaction appears in green; the AR LBD appears in light blue,
and the fenamic acid molecule, which highlights to BF3 surface, appears in dark blue.
Superposition was generated using the Topp program in CCP4. This figure shows similarity of
domain orientations between the ligand binding domains of the two receptors at their interface
with β-catenin.
2.3.2 FKPB52/β-catenin Effects on AR Potentiation
The crystal structure and superposition study shown in Figure 2.1 presented data which
warranted investigation of β-catenin’s regulation of AR, and it was important to compare this
with the regulation of AR by FKPB52, which we also believed to be mediated through AR’s BF3
surface. To determine if FKBP52 and β-catenin would function competitively or in concert in
regulation of AR, luciferase assays were conducted in mammalian expression systems. We
investigated if the ligand binding domain of the androgen receptor would be differentially
regulated by the proteins FKBP52 and β-catenin when the proteins were introduced individually
versus together in the HeLa cell line. Because wild-type β-catenin is rapidly phosphorylated by
GSK3β to undergo degradation when it is over-expressed in a cell (70), we utilized the β-catenin
S33Y mutant, which is resistant to GSK3β-mediated phosphorylation.
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Figure 2.1: β-catenin Binds a Surface of LRH-1 Ligand Binding Domain That Overlaps with the
Putative FKBP52 Interaction Surface.

A. The AR LBD crystal structure (cyan) bound to a BF3 binding molecule (purple) overlaid on
the LRH-1/ β-catenin (green) co-crystal structure. Note that the predicted β-catenin binding site
on AR overlaps with the putative FKBP52 interaction site (BF-3 surface).
B. Space-filling model of LRH-1/ β-catenin (green) and AR BF-3 (gray).
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A mammalian vector expressing the AR LBD fused to the Gal4 DNA binding domain
was employed in co-transfection assays of HeLa cells with the Gal4-tk-luc reporter. β-catenin
and FKBP52 were co-transfected alone and together, in the presence of ethanol or DHT, and a
vector was used as a transfection control. In the absence of DHT, none of the transfected groups
signaled, verifying that the Gal4-AR LBD was responsive to DHT treatment. In the presence of
DHT, induction was influenced greatly by the transfected plasmids.

The Gal4/AR LBD

increased Gal4-dependent transcription appropriately. When β-catenin was transfected alone, it
increased transcription eight-fold.

Transcription doubled when FKBP52 was transfected.

Instead of exhibiting competition, when the two proteins were transfected together, activity was
synergistic; transcription increased fifteen-fold over vector alone (Figure 2.2A).
An ideal model system would provide a negative background for studying the proteins
FKBP52 and β-catenin. Our lab possessed a mouse embryonic fibroblast cell line generated
from FKBP52 knockout mice (11). Because MEFs are a hearty, stable cell line lacking FKBP52
and AR, and MEFs express FKBP51 nearly undetectable levels, this line was utilized for the
initial characterization of these proteins. Mammalian expression plasmids were transiently
transfected into 52 KO MEF cells to determine the effects of co-transfecting β-catenin alone,
FKBP52 alone, and β-catenin with FKBP52, along with the AR-inducible Probasin luciferase
reporter plasmid and a β-galactosidase reporter plasmid to normalize for transfection efficiency.
Following a 16-hour hormone induction period with 10 pM DHT or vehicle control to dissect
hormone-specific effects, cells were lysed, and AR-mediated reporter assays were conducted.
Following normalization for transfection efficiency, reporter expression was quantified as a
percentage over maximum signaling for each of the following treatment groups:

vector,

FKBP52, β-catenin, FKBP52 + β-catenin, β-catenin S33A, and FKBP52 + β-catenin S33A.

51

Figure 2.2: FKBP52 and β-catenin Synergize in HeLa and 52KO MEF Cells.
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Figure 2.2: FKBP52 and β-catenin Synergize in HeLa and 52KO MEF Cells.
A. Reporter assays were performed in HeLa cells using the Gal4-tk-Luc reporter system in the
presence or absence of Gal4-AR LBD, β-Catenin, FKBP52, or hormone (DHT). The data
represent averages (plus SDs [error bars]) of at least three independent experiments. Using the
Bonferroni statistical analysis follwing a one way Anova test with an alpha value of 0.05, Gal4AR LBD luc reporter activity is significantly enhanced in cells transfected with FKBP52/ S33Y
β-Catenin as compared to those transfected with either FKBP52 or S33Y β-Catenin when
comparing cells enhanced with DHT, with a p-value < 0.001 (***).
B. Wild type AR, the AR-inducible luciferase reporter plasmid, and the constitutively active βgalactosidase reporter plasmid were co-transfected simultaneously into 52KO MEFs with each of
the plasmids indicated for the different treatment groups. Cells were induced with 10 pM DHT
(black bars) or ethanol (gray bars). Following cell lysis, AR transcriptional activity was tested
through a luciferase assay, followed by a normalizing β-galactosidase assay. Bars represent
luciferase reporter expression/ β-galactosidase reporter expression and are averages (plus SDs
[error bars]) of at least three independent experiments. Using the Bonferroni statistical analysis
follwing a one way Anova test with an alpha value of 0.05, AR reporter activity is significantly
enhanced in cells transfected with FKBP52/ wild typeβ-Catenin as compared to those
transfected with either FKBP52 or wild type β-Catenin when comparing cells enhanced with
DHT or treated with vector for each perspective group, with a p-value < 0.001 (***). AR
reporter activity is also significantly enhanced in cells transfected with FKBP52/ S33A βCatenin as compared to those transfected with either FKBP52 or S33A β-Catenin when
comparing cells enhanced with DHT or treated with vector for each perspective group, with a pvalue < 0.001 (***).
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FKBP52 doubled AR activity as compared with vector in the presence of DHT. βcatenin slightly enhanced activity in the presence or absence of hormone, and that regulation was
further enhanced when the GSK3β phosphorylation deficient mutant, β-catenin S33A, was
utilized. Synergism was clearly seen through a thirteen-fold induction over vector signaling
when β-catenin and FKBP52 were co-transfected in the presence of DHT. Without DHT, the
induction was approximately six-fold whether using wild type or S33A β-catenin. Synergism is
maximized to twenty-fold when the S33A form of β-catenin is used in the presence of DHT, as
would be expected (Figure 2.2B).
2.3.3 β-catenin and FKBP52 Proteins Interact Directly in vitro
It is currently understood that FKBP52 must be bound to the AR complex to exert its
effects on AR-mediated transcription. Steroid hormone receptors bind Hsp90, and Hsp90 binds
FKBP52 (125, 126). The Hsp90 inhibitor geldanamycin prevents association of FKPB52 with
AR in in-vitro interactions employing co-IP reactions with rabbit reticulocyte lysate (11). A
K354A mutation in the TPR region of FKBP52 prevents the binding of FKBP52 to Hsp90. This
mutation is able to prevent regulation of GR by FKBP52 (12). However, it was an undeniable
possibility that we had discovered a new mechanism of regulation of AR by FKBP52 that
operated independently of any other proteins.
To determine if β-catenin and FKBP52 could interact in the absence of the androgen
receptor complex or other proteins, GST pull-down assays were performed using GST-tagged βcatenin and purified FKBP52 proteins. FKBP52 did not significantly bind the beads in the
absence of β-catenin, yet GST-tagged β-catenin did bind the beads, indicating that the interaction
was specific. An approximation was made to add equimolar levels of starting material, as
indicated by the input visualized on the blot. GST-tagged, purified β-catenin binds FKBP52
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directly in the absence of other proteins, as assessed by the Western blot of glutathionesepharose bound beads (Figure 2.3).
In addition to the interaction studies discussed above, our collaborators at the Methodist
Hospital in Houston (Dr. Paul Webb’s group) have performed a number of coimmunoprecipitations. Their preliminary data validates our findings of a direct interaction
between FKBP52 and β-catenin and shows clear evidence of a heteromeric complex containing
FKBP52, β-catenin, and AR LBD.
2.3.4 Characterization of FKBP52’s Structural Components for β-catenin Synergism
Since β-catenin and FKBP52 can interact in vitro in the absence of other proteins, we
surmised that regulation of AR by these proteins could operate independently of what has
previously been characterized in FKBP52 studies. It was important to determine the functional
effects of FKBP52 muations on FKBP52/β-catenin synergism. Initial studies of FKBP52’s
regulation of steroid hormone receptors have shown that FKBP52’s regulation is dependent on
structural integrity of the proline-rich loop over the PPIase domain (12, 45). The mutants F130Y,
F67Y, W90L, and Y57A abrogate PPIase activity without disrupting the conformation of the
proline-rich loop or inhibiting FKBP52 regulation of AR (45). We wished to determine if PPIase
activity was necessary for FKBP52/β-catenin synergism. Therefore, site-directed mutagenesis
was performed to generate the F130Y and F67Y mutations on FKBP52 in a mammalian
expression plasmid. Effects of these mutations were examined in our 52KO MEF system. Wild
type AR, the AR-inducible Probasin reporter luciferase plasmid, and the β-galactosidase reporter
plasmid (for normalizing transfection efficiency) were transiently transfected simultaneously
with each of the plasmids indicated for the different treatment groups into 52 KO MEF cells.
Cells were induced with 10 pM DHT (black bars) or vehicle control (gray bars).
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Figure 2.3: FKBP52 and β-catenin Interact in GST Pull-down Assay.

In-vitro GST-pull down assays were performed with purified, recombinant FKBP52 and GSTTagged, purified β-catenin. Proteins were visualized with primary antibodies specific to human
FKBP52 and β-catenin.
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Following 16-hour incubation, cells were lysed, AR transcriptional activity was tested
through a luciferase assay, and transfection efficiency was normalized through a β-galactosidase
assay.

These results confirmed that PPIase activity is not required for β-catenin/FKBP52

synergism to occur (Figure 2.4A). Though only the FKBP52 F130Y mutant is shown, results
were also replicated using the FKBP52 F67Y PPIase-deficient mutant.
Previous studies of the FKBP51 double mutant A116V/L119P demonstrated the
importance of the overhanging loop of the PPIase domain in regulation of AR (45). This region
was studied because the FD67DV mutation, which disrupted PPIase activity (but also distorted
the conformation of the PPIase domain), completely prevented potentiation of GR and reduced
AR potentiation as well (12), yet other mutations which disrupted PPIase activity had no effects
on FKBP52 potentiation of receptor. The FKBP51 L119P/A116V mutant was generated as a
result of information from random mutagenesis of FKBP52’s closely related protein FKBP51,
which conferred FKBP52-like potentiation of AR. The L119P mutation results in a change in
conformation of the overhanging loop that makes FKBP51 more structurally similar to FKBP52
(45). Thus, these studies demonstrated that FKBP51 and FKBP52 are functionally divergent
proteins by virtue of only a few residues in the proline-rich loop. To determine if β-catenin could
synergize with FKBP51 or the gain-of-function mutant FKBP51 A116V/L119P, we transiently
transfected these plasmids alongside β-catenin and FKBP52 as described above. Indeed, the
FKBP51 double mutant synergized in the presence of DHT with β-catenin but not with wild type
FKBP51 (Figure 2.4B). This establishes the importance of preserving structural integrity of the
proline rich loop for FKBP52/ β-catenin synergism.
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Figure 2.4: The Domain Requirements for FKBP52/β-catenin Synergy Mirror Those of
FKBP52–Mediated Potentiation of Receptor Function
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Figure 2.4: The Domain Requirements for FKBP52/β-catenin Synergy Mirror Those of
FKBP52–Mediated Potentiation of Receptor Function

Wild type AR, the AR-inducible luciferase reporter plasmid, and the constitutively active βgalactosidase reporter plasmids were co-transfected simultaneously with each of the plasmids
indicated for the different treatment groups. Cells were induced with 10 pM DHT (black bars) or
ethanol (gray bars). Following cell lysis, AR transcriptional activity was tested through a
luciferase assay, followed by a normalizing β-galactosidase assay. The data shown are averages
(plus SDs [error bars]) of four independent experiments.
A. The PPIase-deficient mutant FKBP52-F130Y is compared to wild type FKBP52 for receptor
potentiation. Using the Bonferroni statistical analysis follwing a one way Anova test with an
alpha value of 0.05, AR reporter activity is significantly enhanced in cells transfected with
FKBP52-F130Y / S33A β-Catenin as compared to those transfected with either FKBP52-F130Y
or S33A β-Catenin when comparing cells enhanced with DHT or treated with vector for each
perspective group, with a p-value < 0.001 (***). The already established wild type FKBP52/
S33A β-Catenin group is also statistically significant at p < 0.001 (***). There is no statistical
significance between transfections using wild type FKBP52/ S33A β-Catenin as compared to
F130Y FKBP52/ S33A β-Catenin when vector is utilized, but there is a statistical significance at
(p < 0.001 (***)) when hormone is added to those transfected groups.
B. DM refers to the A116V /L119P double mutation in the FKBP51 proline-rich loop.

This

gain-of-function mutant allows FKBP51 to potentiate receptor similarly to FKBP52 was
compared against wild type FKPB52 for receptor potentiation. Using the Bonferroni statistical
analysis follwing a one way Anova test with an alpha value of 0.05, AR reporter activity is
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significantly enhanced in cells transfected with FKBP51-A116V /L119P / S33A β-Catenin as
compared to those transfected with either FKBP51-A116V /L119P or S33A β-Catenin when
comparing cells enhanced with DHT or treated with vector control for each perspective group,
with a p-value < 0.001 (***). The already established FKBP52/ S33A β-Catenin group is also
statistically significant at p < 0.001 (***). There is no statistical significance between
transfections using FKBP52/ S33A β-Catenin as compared to FKBP51-A116V /L119P / S33A βCatenin when vector is utilized, but there is a statistical significance at (p < 0.001 (***)) when
hormone is added to those transfected groups.
C. The Hsp90 deficient-binding mutant FKBP52-K354A was compared against wild-type
FKBP52 for receptor potentiation. Using the Bonferroni statistical analysis follwing a one way
Anova test with an alpha value of 0.05, AR reporter activity is significantly enhanced in cells
transfected with FKBP52-K354A / S33A β-Catenin as compared to those transfected with either
FKBP52-K354A or S33A β-Catenin when comparing cells enhanced with DHT or treated with
vector for each perspective group, with a p-value < 0.001 (***). The already established
FKBP52/ S33A β-Catenin group is also statistically significant at p < 0.001 (***). There is no
statistical significance between transfections using FKBP52/ S33A β-Catenin as compared to
FKBP52-K354A / S33A β-Catenin when vector or DHT are utilized.
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Since synergism with the FKBP51 double mutant was only 80% of the synergism seen with
FKBP52, it appears that other functional determinants present in FKBP52 besides the
overhanging loop that are absent in FKBP51 are important for full synergism with β-catenin.
Hsp90 chaperoning of the mature receptor complex is important for FKBP52’s regulation
of the receptor. A K354A mutation to the TPR domain of FKBP52 completely prevents its
association with Hsp90 (12, 127). This mutation tremendously decreases GR potentiation by
FKBP52 in a yeast model system (12). Because our earlier findings suggested that β-catenin can
bind FKBP52 in the absence of Hsp90, we wanted to determine the functional effects of the
FKBP52 K354A mutation on FKBP52/β-catenin synergism. Plasmids were transfected and
assays performed as previously described. In the 52 KO MEF model system, we did not see any
changes in AR potentiation due to a K354A mutation on FKBP52’s regulation of AR alone or in
conjunction with β-catenin (Figure 2.4C). Thus, coregulation of AR by FKBP52 and β-catenin
does not require FKBP52 binding to Hsp90.
2.3.5 FKBP52/ β-catenin Synergism Is Reporter-Specific
Though FKBP52 is traditionally viewed as a cytosolic protein, it also associates with
nuclear importins (3, 21) and the cytoplasmic motor protein dynein (22, 128). β-catenin is
generally complexed with the membrane-bound E-cadherin protein, but during wnt-induction or
in cancer pathways, β-catenin localizes to the nucleus (54).

FKBP52/ β-catenin interactions

could therefore occur in the nucleus or in the cytosol and could impact AR signaling at a number
of regulatory points. To determine if FKBP52/ β-catenin synergism could enhance different
promoters to varying degrees, the AR-responsive promoters MMTV (mouse mammary tumor
virus), PSA (prostate specific antigen), and Probasin were examined in the context of luciferase
reporter constructs. Probasin is a promoter found in mice which shows AR-specific and tissue61

specific regulation and is employed to study advanced prostate cancer (129).

The MMTV

promoter was initially characterized in mammalian cells and contains an HRE, which is
inducible by GR, AR, and PR (130, 131). PSA is a promoter that drives the serum biomarker for
prostate cancer, although this gene is also transcribed at lower levels in normal prostate epithelia
(132). Assays used in Figures 2.2b and 2.4 were generated using the Probasin promoter.
Experiments were conducted to determine DNA-specific effects on AR-mediated
transcription. 52 KO MEF cells were cotransfected with one of the three androgen-responsive
luciferase plasmids, the β-galactosidase reporter plasmid for transfection normalization, and the
androgen receptor. DHT dose-response curves were generated for cells under the influence of
each promoter, and the EC20 was used for studies to follow. Initially, transfection cocktails for
each promoter experiment included the reporter plasmids, AR, and plasmids for the following:
vector, FKBP52, β-catenin S33A, or cotransfection of β-catenin S33A and FKBP52. Reporter
gene expression was induced with minimal DHT for 16 hours.

Following cell lysis,

transcriptional activity was assayed through luciferase assays normalized by β-galactosidase
expression. The individual graphs generated by each promoter are seen in Figures 2.5A, 2.5B,
and 2.5C.

Interestingly, in these studies, FKBP52 co-transfection with reporters and AR

increased AR activity twofold over vector, regardless of the promoter. β-catenin co-transfection
had negligible effects, as seen on all promoters. However, great differences in synergism were
seen; Probasin showed the highest degree of synergism at 24-fold over vector but MMTV and
PSA only showed slight increases in effect when β-catenin S33A was added with FKBP52. To
generate the graph seen in Figure 2.5D, the AR promoter-specific luciferase reporter expression
in the presence of FKBP52 and β-catenin was divided by AR activity in the presence of empty
parent vector alone.
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Figure 2.5: FKBP52/β-catenin Synergism Is Reporter-Specific.
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Figure 2.5: FKBP52/β-catenin Synergism Is Reporter-Specific.

Wild type AR, the AR-inducible luciferase reporter plasmid driven by the Probasin (A), MMTV
(B), and PSA (C) promoters, and the constitutively active β-galactosidase reporter plasmids were
co-transfected simultaneously with vector, FKBP52, β-Catenin, or FKBP52 and β-catenin into
52KO MEF Cells. Cells were induced with 10 pM DHT (black bars) or ethanol (gray bars).
Following cell lysis, AR transcriptional activity was tested through a luciferase assay, followed
by a normalizing β-galactosidase assay. The data shown in A, B, and C represent five
independent experiments (plus SDs [error bars]) averaged. The data shown in D is plotted as the
fold induction of averaged AR activity in the presence of DHT for a given promoter in the
presence of FKBP52 and β-catenin co-expression, as compared to AR activity in the presence of
empty vector alone.
A) Using the Bonferroni statistical analysis follwing a one way Anova test with an alpha value of
0.05, Probasin reporter activity is significantly enhanced in cells transfected with FKBP52/
S33A β-Catenin as compared to those transfected with either FKBP52 or S33A β-Catenin alone
when comparing cells enhanced with DHT or treated with vector for each perspective group,
with a p-value < 0.001 (***).
B) Using the Bonferroni statistical analysis follwing a one way Anova test with an alpha value of
0.05, MMTV reporter activity is significantly enhanced in cells transfected with FKBP52/ S33A
β-Catenin as compared to those transfected with solely S33A β-Catenin when comparing cells
enhanced with DHT or treated with vector for each perspective group, with a p-value < 0.001
(***). In the DHT-treated cells transfected with FKBP52 versus cells transfected with FKBP52/
S33A β-Catenin, there was a significant difference with a p-value < 0.01 (**). There is no
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statistical significance between transfections using FKBP52/ S33A β-Catenin as compared to
FKBP52 transfection alone when only vector control is utilized.
C) Using the Bonferroni statistical analysis follwing a one way Anova test with an alpha value of
0.05, PSA reporter activity is significantly enhanced in cells transfected with FKBP52/ S33A βCatenin as compared to those transfected with solely S33A β-Catenin when comparing cells
enhanced with DHT with a p-value < 0.01 (**). There is no statistical significance between
transfections of FKBP52/ S33A β-Catenin as compared to solely S33A β-Catenin when
comparing cells enhanced with vector control. There is also no statistical significance between
cells transfected with FKBP52/ S33A β-Catenin as compared to those transfected with solely
FKBP52, either in the presence or absence of DHT.
D) Using the Bonferroni statistical analysis follwing a one way Anova test with an alpha value of
0.05, Probasin Reporter activity is significantly different from both PSA and MMTV promoter
activity with a p-value < 0.001 (***).
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The only reporter which showed dramatic synergy (up to twenty-four-fold) was the
Probasin promoter. The other reporters exhibited three to fourfold enhancement of receptor
activity over vector in response to FKBP52/ β-catenin S33A co-transfection. Indeed, the coregulation of AR activity by FKBP52 and β-catenin S33A depends on the specific DNA
sequences on which the receptor complex acts.
2.4 DISCUSSION
From the initial idea that β-catenin could potentially regulate the androgen receptor at the
same BF3 surface on which FKBP52 showed the greatest effects (Figure 2.1), this project has
evolved to feature a novel interaction which is previously undocumented in literature. Though
the initial hypothesis that β-catenin and FKBP52 would compete for binding the BF3 surface of
AR was disproven, Chapter 2 documents the characterization of synergism between the proteins,
which is of far greater value to not only the steroid hormone receptor field, but also to
reproductive cancers involving AR.
FKBP52 and β-catenin work in concert to promote synergistic effects on AR signaling
(Figure 2.2). The mere fact that this synergism causes the FKBP52 effect on AR to appear
nominal, demonstrates the depth of this discovery. More importantly, in the absence of FKBP52,
β-catenin does not appear to greatly enhance AR signaling (Figure 2.2B). β-catenin is well
documented as a major contributor to prostate cancer progression, and our studies show that the
role of β-catenin in this pathway can only occur when FKBP52 is present. Previous studies of βcatenin and AR did not utilize cell lines which lacked FKBP52. Preliminary studies of our
collaborators suggest that the β-catenin/AR interactions are strengthened by the presence of
FKBP52. Our findings in GST pull-down experiments suggest that FKBP52 and β-catenin can
bind in the absence of other proteins, including AR and Hsp90 (Figure 2.3). The synergism is
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not produced as a result of FKBP52 PPIase activity (Figure 2.4A), nor is it dependent on Hsp90
(Figure 2.4C), but it is related to FKBP52’s regulatory surface, the overhanging proline rich
loop above the PPIase pocket (Figure 2.4B). Lastly, the DNA sequence-specific effects on
synergism as seen in the reporter studies suggest that the FKBP52/β-catenin synergistic effect is
occurring at the transcriptional level (Figure 2.5).
These findings present a novel role for FKBP52 in AR pathways, in which the protein is
critical for β-catenin enhancement of AR activity. Further studies are needed to continue to
characterize this interaction and to develop better drugs to target it in cancer therapies. Chapter 3
highlights an initial examination of novel combinations of treatments, and Chapter 4 illustrates
the significance of our findings in prostate cancer cell lines.
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Chapter 3: Investigation of AR BF3 Surface Inhibitors, Androgen
Antagonists, Hsp90 Inhibitors, or Combinations of Inhibitors in Prevention of
FKBP52/β-catenin Synergism
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3.1 RATIONALE
Our laboratory developed a small molecule inhibitor, MJC13, which effectively abrogates
FKBP52’s potentiation of AR in yeast, MEFs, MDA-kb2 cells, and the prostate cancer cell lines
LNCaP, LAPC4, VCaP, and 22RV1 (103). This inhibitor is structurally similar to some of the
fenamic acid inhibitors used by the UCSF Fletterick lab, which bind a novel regulatory surface,
BF3, of the androgen receptor. The BF3 surface appears to affect the orientation of AF-2,
thereby regulating the recruitment of coactivators. When Flettericks’ inhibitors bound BF3, the
interaction weakened coactivator binding affinity on AF-2 (101). Feasibly, MJC13 could operate
similarly, but it contacts different residues than Fletterick’s compounds on the BF3 surface as
predicted by in silico docking simulations. Functionally, MJC13 shows different trends from
Fletterick’s flufenamic acid as MJC13 is specific in blocking the FKBP52 effect on AR (and
GR) potentiation. With flufenamic acid, the effects of FKBP52 inhibition are not as dramatic; it
inhibits the receptors with less specificity for the FKBP52 effect. Therefore, a new mechanism
of action is suspected. Western blots reveal that as MJC13 increases in concentration, the
concentration of AR and FKBP52 proteins increases in the cells, similarly to the use of
nonhydrolyzable ATP analogues that block Hsp90 complex dissociation.

Employment of

cellular fractionation shows that hormone-induced translocation is indeed blocked in a dosedependent manner by MJC13. Enzyme-linked immuno sorbent assays (ELISA) reveal that
MJC13 decreases secretion of PSA in LNCaP and VCaP cells. Western blots show a decrease in
the AR-dependent proteins FKBP51 and PSA as MJC13 concentrations increase. Quantitative
PCR reveal that transcription of both PSA and Human Transmembrane protease serine 2
(TMPRSS2) are prevented by MJC13.

In 22RV1 cells, however, MJC13 only affects the

androgen-responsive receptor with an intact LBD but not the constitutively active AR of this cell
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line. These trends suggest that MJC13 prevents AR complex dissociation, thereby freezing AR
in the cytoplasm and blocking transcription of AR-regulated genes through interaction with the
AR LBD (103).
17AAG is a benzoquinone ansamycin derivative of geldanamycin which directly binds
Hsp90 at its N-terminus to inhibit ATP binding, thereby inhibiting Hsp90 and even leading to the
direct degradation of some of its client proteins (133, 134). KU174 is a second-generation
derivative of novobiocin, which binds Hsp90 at the C-terminus to inhibit its activity (135).
KU174 was developed as an alternative Hsp90 inhibitor to 17AAG to avoid inducing HSF1 and
initiating the chemoprotective heat shock response in cells (135-137). Profiles of client protein
degradation both overlap and contrast in comparisons of 17AAG with KU174 (135).
Bicalutamide is a nonsteroidal toluidide, a classic androgen antagonist that binds the
hormone binding pocket of AR to prevent binding of DHT (138, 139). Experiments have
suggested multiple mechanisms of action for this drug. In one study, a co-immunoprecipitation
(co-IP) with AR in LNCaP cells incubated for 30 minutes at 37°C with Bicalutamide pulled
down Hsp90, Hsp70, and FKBP52, even when hormone was added. Additionally, no AR was
found in nuclear extracts incubated with Bicalutamide and hormone (99). However, Masiello et
al. suggested that AR’s localization to the cytoplasm could be a temporary state with this drug.
When injected every other day for two weeks into mice with normal prostate epithelium,
Bicalutamide-treated mice exhibited the same expression of nuclear AR as PBS-treated mice.
Human bone marrow biopsies of malignant prostate cancer patients treated with Bicalutamide
displayed nuclear AR in immunostained tissues. Bicalutamide or DHT was next incubated with
LNCaP cells grown on coverslips for two hours and fixed for immunofluorescence. In two
hours’ time, Bicalutamide induced nuclear translocation of AR just as efficiently as 10 nM DHT.
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Chromatin immunoprecipitation (ChIP) assays in LNCaP and AR-negative DU145 prostate
cancer cells showed that Bicalutamide stimulated endogenous AR binding to the PSA enhancer.
To shed light on the role of this anti-androgen inhibitor, a mammalian-two-hybrid proteinbinding assay showed that Bicalutamide prevented the AR N- and C-terminal interactions for
transactivation. Also, SRC-1/SRC-2 transfection did not stimulate Bicalutamide enhancement of
AR activity (140), implying that coactivator recruitment is affected by Bicalutamide.
What is fascinating is that Bicalutamide seems to stimulate apoptosis even in ARnegative cell lines. Floyd et al. studied the spectrum of prostatic cell lines, from the androgensensitive benign hyperplasia-derived PWR-1E cells to the malignant, AR-negative PC-3 and DU145 cells, for mechanisms of apoptosis. In all lines, Bicalutamide induced cell death. In the
PWR-1E cells, apoptosis occurred within 24 hours and was caspase-dependent but not calpaindependent. For the PC-3 line, the mechanism was partially caspase dependent, partially calpaindependent (141). Therefore, Bicalutamide’s mechanisms of action may differ depending on the
androgen receptor dependency of the cell line.
The chemical structures of the compounds MJC13, Bicalutamide, 17AAG, and KU174
are illustrated in Figure 3.1.
Three main approaches to counteract FKBP52/ β-catenin synergism on AR could be to
block the FKBP52/Hsp90 interaction, to prevent AR BF3 interactions with proteins, and to
abrogate the β-catenin/AR interaction. At the heart of all of these interactions is the AR protein.
We chose to focus on the blocking of AR BF3 interactions with the drug MJC13. By adding in
the two classes of drugs anti-androgens and Hsp90 inhibitors, we believed that we could
dramatically decrease synergism. Specifically, Bicalutamide would block ligand from binding
receptor and conversely, the Hsp90 Inhibitors 17AAG and KU174 would prevent the receptor
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Figure 3.1: Chemical Structures of Compounds Utilized
Chemical structures of the compounds MJC13 (A), Bicalutamide (B), 17AAG (C), and KU174
(D) are represented above.
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from contacting Hsp90. Meanwhile MJC13 would prevent the interaction of the BF3 surface
with FKBP52/ β-catenin. Figure 3.2 documents the proposed targets of not only these drugs but
also drugs to be considered in the future and illustrates the rationale behind the combination
approach utilized in this aim.
MJC13’s IC50 is 0.45uM in 52KO MEF cells co-transfected with AR, FKBP52, and
reporter plasmids. In preliminary studies, we co-transfected the above plasmids alongside βcatenin into 52KO MEFs and generated a dose-response curve to see if MJC13’s IC50 changed in
response to the additional β-catenin, but it did not greatly affect the value.

Our initial

hypothesis was that MJC13 would block the FKBP52 component of FKBP52/β-catenin
synergism more potently if administered in conjunction with Hsp90 Inhibitors or the antiandrogenic drug Bicalutamide. To investigate this hypothesis, we performed co-transfections of
AR, FKBP52, and reporter plasmids into 52KO MEF cells, and then we administered the drug
treatment for an hour soak prior to DHT induction or vector administration as follows:
A.

A range of MJC13 doses administered with either the IC50 dose of 17AAG,
KU174, or Bicalutamide

B.

A range of doses of 17AAG, KU174, or Bicalutamide administered with the
IC50 dose of MJC13

Reporter assays would follow to assess dose-response relationships and to determine IC50
values.
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Figure 3.2: Proposed Targets of Drug Combinations

To block FKBP52/β-catenin synergism, three approaches could be taken to block each of the
three components. A. The FKBP52/Hsp90 interaction could be targeted through a drug such as
FK506. B. An AR BF3 surface inhibitor such as MJC13 could prevent interactions with
proteins such as FKBP52 which bind the BF3 surface. C. The β-catenin/AR interaction could
be blocked. Additionally, the AR LBD could be inhibited through Bicalutamide to block the
ligand from binding receptor or through an Hsp90 Inhibitor such as 17AAG or KU174 which
would prevent the receptor from contacting Hsp90.
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3.2 MATERIALS AND METHODS
For assays, immortalized 52 KO MEF cells were cultured at 5% CO2 in HyClone
MEM/EBSS with 2 mM L-glutamine (Thermal Scientific, Logan, UT) supplemented with 10%
Charcoal/Dextran Treated FBS (HyClone, Logan, UT) twenty-four hours prior to transfection.
Cells were plated at a concentration of 2 x106 cells/well in 6-well plates at approximately 80%
confluence. They were transfected in duplicates using lipofectamine 2000 (Invitrogen, Carlsbad,
CA) according to the manufacturer’s protocol. Transfections were performed for 5 hours using a
DNA to lipofectamine ratio of 1:3 in MEM-EBSS lacking FBS. The transfection cocktail was
mixed as follows: 50 ng of the pCMVβ β-galactosidase normalizing reporter plasmid (Clonetech,
Mountain view, CA), 400 ng of the pT81 (American Type Culture Collection, Manassas, VA)
plasmid expressing firefly luciferase reporter driven by the androgen-dependent Probasin
promoter, 800 ng of the pCI-Neo plasmid (Promega, Madison WI) expressing human AR, and
800 ng of either the pCI-Neo plasmid expressing FKBP52, or with 800 ng of pCI-Neo plasmid as
a normalizing vector. In the initial study, 800 ng of pCMV-Sport6 plasmid (Open Biosystems,
USA) expressing β-catenin was also transfected.
Twenty-four to thirty hours after transfection, medium was replaced and inhibitor was
added for a 45 minute to 1 hour soak followed by treatment with DHT (concentrations used
corresponded with the EC50 of DHT) for 16 hours. Inhibitors were stored in dimethyl sulfoxide
(DMSO) and were added individually at a volume equivalent to 0.5% of the media volume in
each experiment. For monotreatment studies, a range of doses were given of single inhibitor
treatments with the following inhibitors: MJC13 (Sigma Aldrich, St. Louis, MO), Bicalutamide
(Sigma Aldrich, St. Louis, MO), 17-AAG (A.G. Scientific, San Diego, CA), or KU174 which
was kindly donated by B.S. Blagg, University of Kansas (135). In the first set of combinatorial
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inhibitor studies, the IC50 dose of the drugs Bicalutamide, 17-AAG, or KU174 was added to each
well at a volume equivalent to 0.5% of the media volume simultaneously with a range of doses
of MJC13, also at a volume equivalent to 0.5% of the media volume. In the second set of
combinatorial inhibitor studies, the IC50 dose of the drug MJC13 was added to each well at a
volume equivalent to 0.5% of the media volume simultaneously with a range of doses of
Bicalutamide, 17-AAG, or KU174, also at a volume equivalent to 0.5% of the media volume.
After approximately sixteen hours of incubation with hormone, cells in each well were
lysed using 100µL M-PER (Pierce, Rockford, IL) supplemented with Complete EDTA-free Mini
Protease Inhibitor (Roche, Manheim, Germany) and spun using a microcentrifuge to remove
impurities. Luciferase expression was quantified by mixing 40 µL cell lysate with 100 µL of
luciferase assay reagent (Promega, Madison, WI) in a single well for each sample on a 96 well
plate. β-galactosidase expression was quantified by adding 20 µL cell lysate with 100 µL of Gal
Screen Reagent (Tropix, Bedford, MA). The 96-well plates were incubated at room temperature
(incubation time was approximately 5 minutes for the luciferase assay and 2 hours for the βgalactosidase assay), followed by quantification of luminescence by a microplate luminometer
(Luminoskan Ascent, Thermo Labsystems). Luminescence was measured in RLU. The
transfection-efficiency normalized levels of reporter expression (luciferase RLU/ β-galactosidase
RLU) were reported in graphical form using Graphpad Prism software. Data was represented as
the mean (+/- standard deviation) of two separate samples, and figures are composite graphs
representing data from at least three independent experiments.
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3.3 RESULTS
3.3.1 Drug Profiles for MJC13, 17AAG, KU174, and Bicalutamide in 52KO MEF Cells
The AR BF3 surface inhibitor MJC13 effectively blocks FKBP52/β-catenin synergism in
52 KO MEF cells (Figure 3.3). To generate this graph, 52 KO MEF cells were co-transfected
with wild type AR, FKBP52, β-catenin, the AR-inducible Probasin luciferase reporter plasmid,
and the β-galactosidase reporter plasmid (for normalizing transfection efficiency). Cells were
soaked with a range of inhibitor concentrations or DMSO vehicle control for forty-five minutes,
followed by induction with the half maximal effective concentration (EC50) of DHT for this cell
line. Following 16 hour incubation, cells were lysed, AR transcriptional activity was tested
through a luciferase assay, and transfection efficiency was normalized through a β-galactosidase
assay.

This dose-response study was performed in triplicate, and a representative curve was

selected as shown in the figure.
To increase the potency of MJC13, drugs 17AAG, KU174, and Bicalutamide were also
examined using a combinatorial approach with MJC13. β-catenin addition to the transfection
cocktail did not significantly impact the EC50 value of MJC13 as reported in literature when only
AR and FKBP52 are present (103), and since β-catenin is expressed endogenously in these cells,
our studies of drug compounds were conducted solely in the presence of AR and FKBP52.
The Hsp90 inhibitors 17AAG and KU174 were selected primarily for the targeting of
Hsp90’s other (non-steroid hormone receptor) clients, which might participate in a FKBP52/β-

77

Figure 3.3: The AR BF3 Surface Inhibitor MJC13 Effectively Blocks FKBP52/ β-catenin
Synergism in 52 KO MEF Cells

Wild type AR, the AR-inducible luciferase reporter plasmid driven by the Probasin promoter, the
constitutively active β-galactosidase reporter plasmid, β-catenin, and FKBP52 were cotransfected simultaneously in 52KO MEF cells. The following day, cells were treated with a
range of doses for forty five minutes with MJC13 prior to addition of the EC50 dose of DHT. 16
hours after induction, cells were lysed, and AR transcriptional activity was tested through a
luciferase assay, followed by a β-galactosidase assay to control for transfection efficiency.
Graphs are plotted as reporter expression (AR-induced luciferase activity/β-galactosidase
expression) against concentration of inhibitor (plus SDs [error bars] of duplicates). The data
shown are representative graphs indicative of at least three independent experiments.
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catenin cascade. Because the binding sites as well as profiles of client degradation due to
KU174 and 17AAG are different, we wished to employ both inhibitors in our studies with
MJC13. Bicalutamide was chosen due to its anti-androgenic activity (138, 139), its prevention
of N-C terminal interactions for AR dimerization, its negative effects on coactivator recruitment
and binding (140), as well as its implied cross-talk with other pathways that induce apoptosis
(141). Lastly, in SW480 cells, Bicalutamide given at the same time as DHT prevents AR/βcatenin interactions (142), but the mechanism of inhibition is not clear. It was believed that the
above drugs would integrate inhibition of other pathways in addition to MJC13.
Prior to administering combinatorial therapies of MJC13 with other drugs, each drug was
administered individually to establish a baseline dose-response curve for the drug in 52 KO MEF
cells. 52 KO MEF cells were co-transfected with wild type AR, FKBP52, the AR-inducible
Probasin luciferase reporter plasmid, and the β-galactosidase reporter plasmid (for normalizing
transfection efficiency). Cells were soaked with a range of inhibitor concentrations or DMSO
vehicle control for forty-five minutes, followed by induction with the half maximal effective
concentration (EC50) of DHT for this cell line. Following 16 hour incubation, cells were lysed,
AR transcriptional activity was tested through a luciferase assay, and transfection efficiency was
normalized through a β-galactosidase assay.

Figure 3.4 shows dose-response curves for the

compounds MJC13 (A), Bicalutamide (B), 17AAG (C), and KU174 (D). Although each drug’s
dose-response study was performed in triplicate, a representative curve was selected for each
drug, as shown in the figure.

79

Figure 3.4: Dose-Response Curves of MJC13, Bicalutamide, 17AAG, and KU174 in 52KO MEF
Cells Induced with DHT

80

Figure 3.4: Dose-Response Curves of MJC13, Bicalutamide, 17AAG, and KU174 in 52KO MEF
Cells Induced with DHT

Wild type AR, the AR-inducible luciferase reporter plasmid driven by the Probasin promoter, the
constitutively active β-galactosidase reporter plasmid, and FKBP52 were co-transfected
simultaneously in 52KO MEF cells. The following day, cells were treated with a range of doses
for forty-five minutes with the drugs (A) MJC13 (red), (B) Bicalutamide (blue), (C) 17AAG
(green), or (D) KU174 (purple) prior to addition of the EC50 dose of DHT. 16 hours after
induction, cells were lysed, and AR transcriptional activity was tested through a luciferase assay,
followed by a β-galactosidase assay to control for transfection efficiency. Graphs are plotted as
reporter expression (AR-induced luciferase activity/β-galactosidase expression) against
concentration of inhibitor (plus SDs [error bars] of duplicates). The data shown are
representative graphs indicative of at least three independent experiments.

81

3.3.2 MJC13 Potency Is Not Improved by the Addition of Bicalutamide, 17AAG, or
KU174 IC50 Doses in 52KO MEF Cells
Once IC50 values were determined for the compounds Bicalutamide, 17AAG, and
KU174, it was then necessary to administer these compounds at their IC50 doses simultaneously
with different doses of MJC13 to generate a combinatorial dose response curve for MJC13 with
each compound. 52 KO MEF cells were co-transfected with wild type AR, FKBP52, the ARinducible Probasin reporter luciferase plasmid, and the β-galactosidase reporter plasmid (for
normalizing transfection efficiency).
Cells were soaked with a range of MJC13 inhibitor concentrations simultaneously with
the IC50 doses of Bicalutamide, 17AAG, or KU174 (or DMSO vehicle control in place of both
drugs) for forty-five minutes, followed by induction with the EC50 of DHT for this cell line.
Following 16 hour incubation, cells were lysed, AR transcriptional activity was tested through a
luciferase assay, and transfection efficiency was normalized through a β-galactosidase assay.
Figure 3.5 shows the resultant dose-response curves for MJC13 with the IC50 dose of
Bicalutamide (A), MJC13 with the IC50 dose of 17AAG (B), and MJC13 with the IC50 dose of
KU174 (C). Unfortunately, none of these compounds achieved the desired effect. Addition of
Bicalutamide or KU174 actually decreased potency by a factor of ten. 17AAG had no effect on
MJC13 potency.
3.3.3 Potency of Bicalutamide, 17AAG, and KU174 are not Improved with the Addition of
MJC13 IC50 in 52KO MEF Cells
While the IC50 value of MJC13 did not appear to favorably change in response to
Bicalutamide, 17AAG, and KU174, it was still possible that MJC13 IC50 dose addition to these
compounds could influence their combinatorial dose-response curves.
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Figure 3.5: Dose-Response Curves for MJC13 in the Presence of IC50 Doses of Bicalutamide,
17AAG, and KU174 and the EC50 Value of DHT
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Figure 3.5. Dose-Response Curves for MJC13 in the Presence of IC50 Doses of Bicalutamide,
17AAG, and KU174 and the EC50 Value of DHT

Wild type AR, the AR-inducible luciferase reporter plasmid driven by the Probasin promoter, the
constitutively active β-galactosidase reporter plasmid, and FKBP52 were co-transfected
simultaneously in 52KO MEF cells. The following day, cells were treated with a range of doses
for forty five minutes with drug MJC13 alongside the IC50 dose of (A) Bicalutamide (blue), (B)
17AAG (green), or (C) KU174 (purple), prior to addition of the EC50 dose of DHT. 16 hours
after induction, cells were lysed, and AR transcriptional activity was tested through a luciferase
assay, followed by a β-galactosidase assay to control for transfection efficiency. Graphs are
plotted as reporter expression (AR-induced luciferase activity/β-galactosidase expression)
against concentration of inhibitor (plus SDs [error bars] of duplicates). The data shown are
representative graphs indicative of at least three independent experiments.
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52 KO MEF cells were co-transfected with wild type AR, FKBP52, the AR-inducible Probasin
reporter luciferase plasmid, and the β-galactosidase reporter plasmid (for normalizing
transfection efficiency). Cells were soaked with the IC50 dose of MJC13 inhibitor
simultaneously with a range of doses of Bicalutamide, 17AAG, or KU174 (or DMSO vehicle
control in place of both drugs) for forty-five minutes, followed by induction with the EC50 of
DHT for this cell line. Following 16-hour incubation, cells were lysed, AR transcriptional
activity was tested through a luciferase assay, and transfection efficiency was normalized
through a β-galactosidase assay.
Figure 3.6 shows the resultant dose response curves for the IC50 dose of MJC13 with a
range of Bicalutamide doses (A), the IC50 dose of MJC13 with a range of 17AAG doses (B), and
the IC50 dose of MJC13 with a range of doses of KU174 (C). Unfortunately, Bicalutamide,
17AAG, and KU174 did not show significant shifts in potency with the addition of the IC50 dose
of MJC13.
3.4 DISCUSSION
The results of all inhibitory studies are visualized in Table 3.1. There was clearly
redundancy of pathway involvement in many cases because there was no improvement in IC50 in
the combinatorial studies. MJC13’s dose-response curve stayed the same with the addition of
17AAG (Figure 3.5B), but it got worse with the addition of Bicalutamide (Figure 3.5A) and
KU174 (Figure 3.5C). It was also seen as Bicalutamide, 17AAG, and KU174 dose-response
curves did not show any potency shifts in response to MJC13 IC50 addition (Figure 3.6).
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Figure 3.6: Dose-Response Curves for Bicalutamide, 17AAG, and KU174 in the Presence of
IC50 Doses of MJC13 and the EC50 Value of DHT
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Figure 3.6: Dose-Response Curves for Bicalutamide, 17AAG, and KU174 in the Presence of
IC50 Doses of MJC13 and the EC50 Value of DHT

Wild type AR, the AR-inducible luciferase reporter plasmid driven by the Probasin promoter, the
constitutively active β-galactosidase reporter plasmid, and FKBP52 were co-transfected
simultaneously in 52KO MEF cells. The following day, cells were treated with a range of doses
for forty-five minutes with a range of doses of (A) Bicalutamide (blue), (B) 17AAG (green), or
(C) KU174 (purple) alongside the IC50 dose of MJC13, prior to addition of the EC50 dose of
DHT. 16 hours after induction, cells were lysed, and AR transcriptional activity was tested
through a luciferase assay, followed by a β-galactosidase assay to control for transfection
efficiency. Graphs are plotted as reporter expression (AR-induced luciferase activity/βgalactosidase expression) against concentration of inhibitor (plus SDs [error bars] of duplicates).
The data shown are representative graphs indicative of at least three independent experiments.
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Table 3.1: Half Maximal Inhibitory Concentrations of MJC13, Bicalutamide, 17AAG, and
KU174 in Isolation and in Combination

Drug(s) in Dose Response

IC50

MJC13
Bicalutamide
Bicalutamide IC50 + MJC13
Bicalutamide + MJC13 IC50
17AAG
17AAG IC50 + MJC13
17AAG + MJC13 IC50
KU174
KU174 IC50 + MJC13
KU174 + MJC13 IC50

1.275x10-6M
1.839x10-7M
1.327x10-5M
5.287x10-7M
1.890x10-5M
3.266x10-6M
1.141x10-5M
1.559x10-5M
1.040x10-5M
1.481x10-5M

Standard
Deviation
2.433x10-7M
4.865x10-8M
1.183x10-5M
6.566x10-7M
5.933x10-6M
7.057x10-7M
1.543x10-5M
6.102x10-6M
1.230x10-6M
1.212x10-5M

This table summarizes the results of all inhibitor trials in Chapter 3 for the drugs Bicalutamide,
17AAG, and KU174, administered alone, dosed as the IC50 in combination with a range of doses
of MJC13, and administered in a range of doses in combination with MJC13 IC50. Average IC50
values of all drug trials and the standard deviations of each condition, representing at least three
tests per drug performed in duplicates, are shown above.
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Addition of the IC50 dose of either Bicalutamide or KU174 to MJC13 actually increased
the IC50 value of the MJC13 curve thereby decreasing its potency to a value tenfold less than
MJC13’s IC50. This was and a hundred-fold less than Bicalutamide’s potency and equal to the
potency of KU174 (Figure 3.5A and C). It is possible that Bicalutamide binding to the LBD of
AR affects the orientation of BF3, and that MJC13 binding to BF3 affects the LBD
conformation. Therefore, the affinity of the opposing binding surface on AR for the compounds
Bicalutamide and MJC13 could be allosterically reduced by the binding these compounds
individually to the LBD or BF3 surfaces. As for the KU174 study, one of the known Hsp90
clients is GSK3β, a serine/threonine kinase, which requires Hsp90 chaperone activity to autophosphorylate and achieve its mature conformation for activity (143). In targeting these GSK3β
intermediates via Hsp90 inhibition, we hypothesize that there could be a decrease in GSK3β
activity. GSK3β is responsible for phosphorylation of free β-catenin, which results in βcatenin’s degradation and the prevention in its participation in nuclear events (70). In inhibiting
Hsp90 chaperoning of GSK3β, even more, free β-catenin could be available to participate in
FKBP52/ β-catenin synergy, thereby driving the synergistic reaction on AR expression and
counteracting the inhibitory effects of MJC13.
It is curious that 17AAG and KU174, both Hsp90 inhibitors with similar potency in 52
KO MEFs when administered in monotherapy (Figure 3.4C and D), did not have the same
effects on the MJC13 dose response. 17AAG IC50 addition to the MJC13 range of doses had no
effect on the MJC13 dose response yet KU174 IC50 addition to the MJC13 range of doses
decreased potency. Since it has been previously shown that there are different mechanisms of
actions for these drugs, it is logical that they could perform differently (135). However, these
drugs showed similar effects when administered in a range of doses in conjunction with the IC50
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dose of MJC13. The addition of MJC13 IC50 with doses of 17AAG or KU174 had no significant
effects on the dose responses of these compounds (Figure 3.6 B and C).
In summary, we believe there are several redundant mechanisms between these drugs.
Because 17AAG acts to stop ATP hydrolysis in Hsp90, it would be expected to prevent the
release of AR from the complex (108). MJC13 freezes the AR complex in the cytoplasm (103).
Since Hsp90 is not believed to participate in nuclear events, the overlapping mechanisms are
feasible. The mechanism of action for KU174 is still being determined, but it certainly binds at
the C-terminus of Hsp90 to exert effects (135). Bicalutamide, in functioning primarily as an
anti-androgen, could have redundant function in that it prevents androgen binding to AR. This
also would indicate a cytoplasmic preference for AR, much like MJC13.
Although the graphs are not shown, preliminary studies in which β-catenin was also
transfected in conjunction with the Hsp90 inhibitors displayed similar dose response curves and
IC50 values to the ones seen in this chapter when FKBP52 was transfected without β-catenin. It
should be noted that endogenous β-catenin is present in the cells used for the studies shown.
Thus, any affects observed upon overexpression of FKBP52 are likely to include coregulation
with endogenous β-catenin. We showed in Chapter 2 that FKBP52/β-catenin synergism could
occur independently of Hsp90, so it is logical that the Hsp90 drugs might not have much effect in
conjunction with MJC13 in blocking synergism.
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Chapter 4: FKBP52/ β-catenin Synergism in Prostate Cancer Cells
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4.1 RATIONALE
Though the majority of our functional studies of FKBP52/β-catenin synergism of AR had
been conducted in 52KO MEF cells, we needed to validate our findings from non-cancerous
pilot studies and establish their significance in prostate cancer cells, as well. Our hypothesis that
we wanted to test was that FKBP52/β-catenin synergism of AR would exist in prostate cancer
cell lines.

Our first goal was to generate FKBP52 and β-catenin knock down cells in both

androgen-dependent and androgen-independent prostate cancer lines. We chose to employ
LNCaP, VCaP, LAPC4, and 22RV1 prostate cancer lines to knock down FKBP52 expression.
Upon successful knock down, we planned to examine AR response to additional β-catenin
transfection when FKPB52 was expressed at normal levels versus at decreased levels using
assays comparing cells transfected with β-catenin or vector in control cells expressing FKBP52
versus the FKBP52 knock down cells. This would allow us to determine if synergism occurs in
the prostate cancer cells as well as to help us to dissect the roles of FKBP52 and β-catenin as
individual components of the synergism.
LNCaP cells are hormone-dependent and were initially isolated from a needle aspiration
biopsy of a prostate cancer patient with metastasis to the lymph node. They represent one of the
first cellular models of prostate cancer (144). LNCaP cells contain the AR-T877A mutation,
which causes promiscuity in binding other hormones (145, 146). They express wild type p53
and also express cytokeratin (CK) 8 and 18.

These cells also are ER positive (144) and

phosphatase and tensin homolog (PTEN) positive (147).
VCaP, androgen-independent cells, were initially isolated from a patient with vertebral
metastasis of hormone refractory prostate cancer and grown in severe combined
immunodeficiency (SCID) mice xenografts. They possess wild type AR, a mutant p53 gene
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(A248W), and the CKs 8 and 18. They have a broad range of aneuploidy, from hypodiploid to
hypertryploid chromosomes, and many have lost their Y chromosome (144). Additionally, AR is
overexpressed in these cells; mRNA and protein expression levels of AR are ten times greater in
VCaP than LNCaP cells (148).
LAPC-4 is an androgen-dependent cell line derived from lymph node metastasis from a
Stage D prostate cancer patient (149). Cells contain wild-type AR (150), a multi-mutant p53
protein (A175H, P72R, R175H), and express CKs 5, 8, and 18. They exhibit triploid karyotypes
and lack chromosomes Y and 16 (149). Additionally, LAPC-4 cells are PTEN negative (147).
PTEN is a known inhibitor of the Akt pathway (151). Interestingly, β-catenin feeds into the Akt
pathway, which is activated by PTEN loss, so this would be an interesting line in which to
investigate β-catenin-induced synergism (152).
The 22RV1 cell line, a semi-androgen-dependent line, was originally generated through
implantation of an androgen-dependent human prostate cancer tumor in CWR22 xenografts (153,
154), which were serially propagated. The mice were castrated, and 3-10 months later, new
tumors arose which were androgen-independent due to mutations of the AR alleles (155). Cells
from this xenograft model were harvested and developed into the 22RV1 line for use as a
representative in-vitro model system for castrate-resistant human prostate cancer (156). This cell
line contains a constitutively active form of the androgen receptor, which lacks the ligand
binding domain. In the 22RV1 cell line, AR truncation mutants are generated through cleavage
by calpain-2. It appears that a mutation to one of the alleles of the gene has caused the insertion
of genes near the site of calpain cleavage, enhancing the occurrence of receptor cleavage.
Interestingly, some of the human castrate-resistant prostate cancer tissues possess similar
truncated mutants, but not all do (157). Additionally, in the full length AR, the H874Y mutation
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is present. 22RV1 do not respond as robustly to testosterone as the parent CWR22-dependent
cell line. The p53 gene has a Q331R mutation, CK-8 and 18 are expressed, and the line his high
expression of Epidermal Growth Factor (EGF) Receptor members and responds both to
androgens and EGF. There is cancer-like genomic instability in this line as low passage cells are
hyperdiploid and higher passage cells are tetraploid (149).
4.2 MATERIALS AND METHODS
4.2.1 Generation of FKBP52 Knockdown Prostate Cancer Cells
22RV1 and VCaP cells were obtained commercially from the American Type Culture
Collection (ATCC, Manassas, VA). LNCaP cells were a kind gift from Donald Tindall
(Mayo Clinic, Rochester, MN). LAPC-4 cells were obtained from Charles Sawyers (Memorial
Sloan-Kettering Cancer Center, New York, NY) and Robert Reiter (Geffen School of Medicine,
UCLA, Los Angeles, CA). Cells were maintained in the presence of 10% FBS (Atlas Biological,
Fort Collins, CO), and at 5% CO2 at 37 °C. LNCaP and 22RV1 cells were maintained in
Roswell Park Memorial Institute (RPMI)-1640 medium with 25mM HEPES with L-Glutamine
(Thermal Scientific, Logan, UT). VCaP and LAPC-4 cells were maintained in high glucose
Dulbecco’s Modified Eagle Medium (DMEM) medium with 4 mM L-Glutamine, 4500 mg LGlucose, and lacking sodium pyruvate (Thermal Scientific, Logan, UT). Cells were
supplemented with the following reagents, when not provided in medium: 0.5% HEPES
(Thermal Scientific, Logan, UT), 1% Pyruvate (Thermal Scientific, Logan, UT), 1% MEM-non
essential amino acids (Thermal Scientific, Logan, UT), 1% Pen-Strep (Thermal Scientific,
Logan, UT), and 1% L-Glutamine (Thermal Scientific, Logan, UT).
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To generate knockdown cells, all cancer cell lines were maintained in cell culture as
described above, and the pSilencer 2.1 U6 Hygromycin (Ambion, Austin, TX) plasmid was subcloned with the shRNA cassette against FKBP52 from the old pSilencer vector as well as the
scrambled sequence as previously generated by Dr. Cox (11). Cells were infected with lentivirus
per instructions for Mission TR Lentiviral System (Sigma, St. Louis, MO). Briefly, cells were
plated in 96 well plates and allowed to attach in the 37°C, 5%CO2 incubator. Media was
removed and cells were primed with media supplemented with hexadimethrine bromine to
increase viral uptake. Viral particles and vector were added, and the mixture was incubated
overnight in the absence of Hygromycin. After 24 hours, the media was removed, and clones
were selected by repeated cycles of pooling and plating in 150 µg/µL hygromycin every 3 days.
Hygromycin concentration for selection was determined by titration prior to the beginning of the
experiment.
4.2.2 Western Blot of Cellular Lysates
To assess efficiency of knockdown of FKBP52, Western immunoblots were performed
using the prepared lysates of control 22RV1 cells and knockdown 22RV1 cells, harvested with
MPER as described above. After quantifying protein concentrations of each cell lysate, an
equivalent amount of protein was loaded for each sample lane on Criterion gels (BioRad,
Hercules, CA), and proteins were separated by electrophoresis. The proteins were then
transferred from the gels to Immobilon PVDF membranes (Millipore, Bedford, ME), and the
membranes were blotted for protein expression. The following mouse monoclonal antibodies
were used as primary antibodies: anti-FKBP52 Hi52d (epitope in FK1 domain) and antiglyceraldehyde-3-phosphate dehydrogenase (Biodesign International, Saco, ME) as a loading
control. The rabbit polyclonal antibody anti-AR (N-20 Santa Cruz, Santa Cruz, CA) was used as
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primary antibody to detect AR. Anti-rabbit and anti-mouse secondary antibodies (Southern
Biotechnology, Birmingham, AL) were used, and the ImmunStar Alkaline Phosphatase Substrate
(BioRad, Hercules, CA) was applied prior to exposing to X-ray films for development and
detection of antibodies.
4.2.3 Assays in 52 Knockdown 22RV1 Cancer Cells
Twenty-four hours prior to experiments, the 22RV1 control and 22RV1 knockdown cells
were plated in RPMI-1640 medium with 25mM HEPES with L-Glutamine (Thermal Scientific,
Logan, UT) supplemented with 10% Charcoal/Dextran Treated Fetal Bovine Serum (HyClone,
Logan, UT). Cells were plated at a concentration of 2 x 106 cells/well in 6-well plates at
approximately 80% confluence.
They were transfected in duplicates using lipofectamine 2000 (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. Transfections were performed for 5 hours at a DNA to
lipofectamine ratio of 1:3 in MEM-EBSS lacking FBS. The transfection cocktail was mixed as
follows: 50 ng of the pCMVβ β-galactosidase normalizing reporter plasmid (Clonetech,
Mountain view, CA) and 400 ng of the pT81 (American Type Culture Collection, Manassas,
VA) plasmid expressing firefly luciferase reporter driven by the androgen-dependent Probasin
promoter. For the β-catenin study in part C, in addition to these plasmids, 800 ng of either the
pCI-Neo plasmid (Promega, Madison WI) as a vector control or 800 ng of the pCMV-Sport6
plasmid (Open Biosystems, USA) expressing the S33A β-catenin (mutated as previously
described) were also cotransfected.
Twenty-four to thirty hours after transfection, medium was replaced with medium
containing DHT or ethanol vehicle control. For part B, a range of doses was used but in part C,

96

175pM DHT was used to induce cells. After approximately sixteen hours of incubation, cells in
each well were lysed using 100µL M-PER mammalian protein extraction reagent (Pierce,
Rockford, IL) supplemented with Complete EDTA-free Mini Protease Inhibitor (Roche,
Manheim, Germany) and spun using a microcentrifuge to remove impurities.

Luciferase

expression was quantified by mixing 40 µL cell lysate with 100 µL of luciferase assay reagent
(Promega, Madison, WI) in a single well for each sample on a 96 well plate.

β-galactosidase

expression was quantified by adding 20 µL cell lysate with 100 µL of Gal Screen Reagent
(Tropix, Bedford, MA). The 96-well plates were incubated at room temperature (incubation time
was approximately 5 minutes for the luciferase assay and 2 hours for the β-galactosidase assay),
followed by quantification of luminescence by a microplate luminometer (Luminoskan Ascent,
Thermo Labsystems).

Luminescence was measured in Relative Light Units (RLU). The

transfection-efficiency normalized levels of reporter expression (luciferase RLU/ β-galactosidase
RLU) were reported in graphical form using Graphpad Prism software and all data was
normalized to 100% expression. All data was represented as the mean (+/- standard deviation) of
at least two separate samples, and figures are composite graphs representing data from at least
three independent experiments.
4.3 RESULTS
FKBP52 Is Required for β-catenin Coactivation of AR in 22RV1 Prostate Cancer Cells
To corroborate our 52 KO MEF studies in prostate cancer cells, we needed to generate a
FKBP52-deficient cell line. The 22RV1 prostate cancer cell line contains two forms of the AR
gene (Figure 4.1.A).
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Figure 4.1: FKBP52 is Required for β-catenin Coactivation of AR in Prostate Cancer Cells
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Figure 4.1: FKBP52 Is Required for β-catenin Coactivation of AR in Prostate Cancer Cells
A. Knockdown FKBP52 in AR-dependent prostate cancer cells is difficult due to a loss of AR
activity and cell proliferation. The constitutively active, truncated AR in 22RV1 supports ARdependent growth enough to generate cell knockdowns.
B. Scrambled and FKBP52 shRNA constructs were stably transfected into 22RV1 cells using a
lentiviral expression system. The selected clones were assessed by Western blot for expression of
the indicated proteins. A DHT dose response curve was generated for control and 52KD 22RV1
cells, data points represented as circles and squares, respectively. The data are averages (plus
SDs [error bars]) of four independent experiments.
C. The AR-inducible luciferase reporter plasmid and the constitutively active β-galactosidase
reporter plasmids were co-transfected simultaneously with either vector or β-Catenin, as
indicated, into 22RV1 control or 22RV1 52 KD Cells. Cells were induced with 175 pM DHT
(black bars) or ethanol control (gray bars). Following cell lysis, AR transcriptional activity was
tested through a luciferase assay, followed by a normalizing β-galactosidase assay. Bars
represent luciferase expression/β-galactosidase expression, normalized to the highest signaling
group. The data are averages (plus SDs [error bars]) of four independent experiments. Using the
Bonferroni statistical analysis follwing a one way Anova test with an alpha value of 0.05,
Probasin reporter activity is significantly enhanced in DHT treated 22RV1 control cells
transfected with S33A β-Catenin as compared to those transfected with vector, with a p-value <
0.001 (***). There was no statistical significance in the 22RV1 control cells transfected with
S33A β-Catenin as compared to those transfected with vector when DHT was not utilized. There
was also no statistical significance in 52KD cells transfected with S33A β-Catenin as compared
to those transfected with vector, when induced by DHT or treated with vector control.
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One allele is full-length but the other allele is a C-terminal truncated form,which is constitutively
active (158). In this line, the full-length AR has a mutation affecting the second zinc finger of
AR due to an in-frame tandem duplication of exon 3 (144, 149).
To generate the knock down cells, short hairpin RNA (shRNA) that specifically targets
FKBP52 mRNA (52KD) or a scrambled shRNA (control) was constructed into a lentiviral
vector, and introduced in conjunction with virus to the 22RV1, VCAP, LNCaP, and LAPC-4
cells. Six clones were generated for the 22RV1 cell line only. All other knockdown cells were
not viable. Real time PCR (RT-PCR) showed >90% reduction in mRNA for the clone chosen
for this study (data not shown). Cell extracts were prepared from each of the cell lines and a
Western Blot was performed for AR, FKBP52, or GAPDH as a loading control. In the 22RV1
knock down cell line, FKPB52 expression was reduced to 20% as compared with the scrambled
sequence, with no changes in overall AR expression or in expression of the housekeeping gene
GAPDH (Figure 4.1.B).
Of the prostate cancer lines attempted for knockdown of FKBP52, only the 22RV1 line
was able to withstand the effects of FKBP52 knockdown due to the loss of AR activity and cell
proliferation. It is believed that 22RV1’s constitutively active AR allows for FKBP52-deficient
growth, but the other prostate cancer lines cannot endure this decrease in AR activity. While this
serves as validation of FKBP52 as an attractive therapeutic target, it also means that 22RV1 cells
are the only prostate cancer cell line in which FKBP52 can be knocked down of the lines we
attempted.
Regarding the β-catenin knockdown cells, despite our best efforts, knockdown efficiency
was very poor. RT-PCR showed that β-catenin could be knocked down most effectively in
22RV1 where efficiency was 50%. We chose not to pursue further studies with these cells.
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Prior to any β-catenin studies in these cell lines, the 22RV1 control and knock down
lines were examined for DHT dose responses. To generate these curves, 22RV1 control and
22RV1 52KD cells were cotransfected with the hormone-responsive Probasin luciferase plasmid
and the β-galactosidase reporter plasmid for transfection normalization. Transfection of AR is
not required in these cells due to its presence endogenously. DHT was administered in a range
of doses and allowed to incubate for 16 hours. Following cell lysis, transcriptional activity was
assayed through luciferase and β-galactosidase assays. Data points represent expression of the
Probasin luciferase reporter normalized to β-galactosidase expression plotted against
concentration of DHT.

The graph was selected as a representation of three independent

experiments, performed in duplicate. In these studies, the EC50 of the hormone within both cell
lines was approximately 300 pM, and the 20% maximal effective concentration (EC20) of the
hormone of both cell lines was approximately 175 pM. We chose to employ the EC20 value for
our transfection studies to characterize synergism.
To determine the importance of FKBP52 in β-catenin regulation of receptor, both control
and 52KD 22RV1 lines were used in transfection studies with or without cotransfection of S33A
β-catenin. Because FKBP52 expression is greatly reduced in the 52KD line, it serves as a nearly
negative background for our studies against the control line, which expresses FKBP52
endogenously. The EC20 DHT dose was utilized for minimal hormone induction in these cells.
22RV1 control and 52KD cells were cotransfected with the hormone-responsive Probasin
luciferase plasmid, the β-galactosidase reporter plasmid for transfection normalization, and either
β-catenin S33A or vector. Reporter gene expression was induced with minimal DHT or vehicle
control for 16 hours. Following cell lysis, transcriptional activity was assayed through luciferase
and β-galactosidase assays. Bars represent the expression of the Probasin luciferase reporter
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normalized to β-galactosidase expression. Reporter expression is expressed as a percentage by
dividing normalized luciferase values by the value obtained by the β-catenin transfected control
cells when induced by 175 pM DHT, the EC20 of DHT.
A comparison of the knockdown groups reveals that in the absence of FKBP52 and the
presence of DHT, β-catenin transfection doubles AR signaling. In the absence of hormone, it
appears that β-catenin has no enhancement of AR activity, whether FKBP52 is present or not.
However, in the wild type group which expresses endogenous levels of FKBP52, DHT addition
alone enhances AR activity fifteen-fold over vector. In comparing DHT-induced wild type cells
transfected with β-catenin versus those transfected with vector, there is approximately a sevenfold induction. Signaling increases to one hundred-fold over baseline vector (without DHT)
when β-catenin is transfected and cells are induced with DHT. This asserts the requirement of
FKBP52 for robust β-catenin regulation of AR in 22RV1 prostate cancer cells (Figure 4.1.C).
Additionally, this result has been repeated by our collaborators at the Methodist Hospital in
Houston (Dr. Paul Webb’s group) in HeLa cells with and without FKBP52 knock down.
4.4 DISCUSSION
The generation of a 52 KD 22RV1 cell line is an accomplishment which will allow our
laboratory to continue to investigate FKBP52 interactions more effectively in prostate cancer
cells. Because knockdown of FKBP52 was impossible in the other prostate cancer cell lines, but
it was effective in 22RV1, it is obvious that this cell line’s unique characteristics allowed it to
survive, establishing the importance of this essential protein for prostate cancer pathways. Most
likely, in the other cell lines, when FKBP52 expression is decreased, AR signaling decreases
significantly, leading to the death or decreased proliferation of the cells. In the 22RV1 cells, the
constitutively active AR likely allows for survival of the cells in the absence of FKBP52.
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While unfortunate that we were unable to generate β-catenin knock down cells, it was not
surprising to us that perhaps these prostate cancer lines may not support growth without βcatenin. We were unable to generate knockouts of β-catenin in yeast, so after several months of
attempting to knock down this protein in mammalian cells beyond 50% mRNA, we decided to
focus our efforts elsewhere.
Our studies of β-catenin transfections in the control versus knock down cells proved the
requirement of FKBP52 for β-catenin to regulate AR in the 22RV1 line. When FKBP52 is at
20% of normal expression in this line and cells are induced with DHT, β-catenin transfection
barely doubles AR signaling, but in the presence of endogenous levels of FKBP52, β-catenin
enhances signaling almost seven-fold. Previous studies in prostate cancer cell lines that deemed
β-catenin important for prostate cancer progression did not examine cells that lacked FKBP52.
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Chapter 5: Conclusions
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5.1 OVERALL PERSPECTIVE
In prostate cancer signaling, free β-catenin regulates AR as a result of activation of wnt
signaling pathways (82), and some have suggested that activation of the PI3K/Akt pathway may
be an upstream regulator of this event. PTEN mutation or loss and WIF-1 down-regulation are
two events which increase the phosphorylation-activation of Akt, thereby deactivating GSK3β
and allowing cytoplasmic β-catenin to become available to participate in nuclear events with AR
(73). Past studies have implicated that β-catenin associates with AR at the AF-2 region of the
receptor (81), but our studies have suggested that it specifically associates with the BF-3 surface,
as seen in Figure 2.1. Additionally, β-catenin is capable of binding AR both when ligand is
bound and when it is absent, but DHT addition increases the amount of β-catenin pulled down by
AR in co-IPs of LNCaP cells (159)
β-catenin is a well-documented coactivator of AR transcription (81, 82, 85, 159, 160),
associating with multiple coactivators and enhancers on promoters. Ligand-bound AR actually
competes with TCF4 for regulation by β-catenin (161), thereby diverging away from its normal
involvement in the TCF4 pathway (162). β-catenin associates with the TATA box binding
protein both in conjunction with the chromatin remodeling complex-associated ATPases Pontin
52 and Reptin 52, as seen by co-immunoprecipitation assays investigating TCF-4’s interaction
partners (163), and it also associates with Brahma Related Gene 1 (Brg-1), a member of the
chromatin remodeling complexes SWItch/Sucrose NonFermentable (SWI/SNF) and chromatin
structure remodeling (Rsc) complex as seen in a yeast two hybrid and a co-immunoprecipitation
(164). Additionally, β-catenin also associates with the transcriptional co-activator and histone
acetylase protein p300 to participate in neoplastic transformation (165). In studying β-catenin’s
regulation of AR promoters specifically, β-catenin recruits coactivator-associated arginine
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methyltransferase (CARM1), a secondary coactivator that is only present on the AR complex
when β-catenin is present (166). Additionally, the p160 coactivator glucocorticoid receptor
interacting protein 1 (GRIP1) and β-catenin exhibit synergistic activity on AR signaling when
co-transfected in CV-1 cells with the MMTV-luc plasmid and AR. While GRIP-1 binds AR
directly, it is also capable of binding β-catenin in the absence of AR. Synergistic effects are
associated with the GRIP-1 autonomous activation domain 2 (AD2), which is used to bind βcatenin (167).
FKBP52’s role as a cochaperone of the Hsp90 complex has been established for decades.
FKBP52 potentiates activity of GR (12), PR (13), and AR (11) but not ER or MR (12). FKBP52
increases hormone binding by AR 5-fold over the affinity exhibited when FKBP51 binds AR
(45). Few nuclear translocation studies of nuclear receptors have been conducted with AR,
specifically; most FKBP52 localization studies have focused on GR. In studies of GR, it appears
that FKBP51 is involved in nuclear shuttling of the constitutively active GRβ or hormone
responsive GRα when not bound by ligand. Upon ligand binding, a shift in preference of GRα
for FKBP52 over FKBP51, a concomitant recruitment of dynein by FKBP52, and the shuttling
of the complex to the nucleus via microtubules occurred (168). However, an earlier paper
suggested that dynein was not required for FKBP52 to potentiate GR. In this study, a dynein 1null yeast strain was employed in comparison with a yeast strain expressing dynein. FKBP52
potentiated both strains similarly (12). Another study bolstered the view that FKBP52 regulates
nuclear transport. In this study, small interfering RNA (siRNA) of the fkbp4 gene encoding
FKBP52 in SH-SY5Y cells resulted in a noticeable decrease in GR recruitment to the nucleus in
response to cortisol administration (169). A recent study suggested that the Hsp90 complex in its
entirety could pass through the nucleus. In this study, GR associated directly with Importin B1
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(ImpB1), and the Hsp90 complex appeared to favor the association of GR with the importin.
Previous studies suggested that upon ligand binding, Hsp90 detached, and the NLS of the
receptor was then readily available to cause receptor transport across the nucleus. This lab crosslinked the Hsp90 heterocomplex so that GR could not release from Hsp90 upon ligand binding.
When Sf9 cells were permeabilized with digitonin, and dexamethasone hormone was added, the
cross-linked complex translocated, showing that transformation (detachment from Hsp90) is not
required for GR to travel to the nucleus. Lastly, FKBP52 appears to interact with the
glycoprotein Nucleoporin 62 (Nup62) only when in an Hsp90-GR complex. In a reticulocyte
lysate immunoprecipitation of Nup62, FKBP52 associated with Nup 62 but FKBP51 did not.
When radicicol, the Hsp90 inhibitor, was used, FKBP52 did not associate with Nup62. When
radicicol was added to cells and fluorescence microscopy was performed, both FKBP51 and
FKBP52 associated perinuclearly, possibly to other nucleoporins. (21). Though the nuclear
translocation studies have been conducted in conjunction with GR, FKBP52 could also play a
role with AR translocation, possibly through mechanisms involving dynein or Nup62, but since
our studies have suggested that FKBP52/β-catenin synergism could occur independently of
Hsp90, anything is possible.
Though broad conclusions cannot be produced through the few studies shown here, it is
obvious that in the 22RV1 cell model, β-catenin regulates AR very little when FKBP52 is not
present (Figure 4.1). Therefore, all the previously mentioned studies by which β-catenin acts as
a coregulator of AR could indeed have exerted their effects in part due to the synergism
exhibited when FKBP52 is present. Additionally, AR associates with proteins such as Hsp90,
p23, and FKBP52 (29) in its mature form when it binds hormone. Since our studies have
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suggested binding of FKBP52 and β-catenin in the absence of Hsp90 and even AR (Figure 2.3),
we have found a new mechanism for FKBP52 regulation of receptor involving β-catenin.
5.2 PROPOSED MECHANISM
In all the functional studies of β-catenin enhancement of AR activity documented in
literature, none have taken place in a FKBP52-deficient cell line. Our studies in 52 KO MEF
cells (Figure 2.2B) as well as the comparisons of 22RV1 cells against the 52 KD line (Figure
4.1) have provided the FKBP52-negative background which was needed to highlight the
obligation of FKBP52 for β-catenin to coactivate AR robustly. In the DHT-induced, HeLa Gal4tk-Luc model which includes endogenous FKBP52, the mere addition of β-catenin causes an 8fold induction over vector, which is increased to 15-fold with additional FKBP52 expression
from transfection (Figure 2.2A). When this is compared to a cell line without FKBP52 such as
the 52 KO MEF model, however, β-catenin exogenous addition does not significantly regulate
the receptor. It is only when FKPB52 is present that β-catenin has an effect, and that effect is
synergism (Figure 2.2B). This finding is validated through the 22RV1 studies (Figure 4.1).
Since it is believed that AR competes with TCF4 for β-catenin binding (161), perhaps the
presence of FKBP52 within the AR complex is enough to shift β-catenin binding to favor AR
over TCF4. Indeed, ligand-bound AR decreases the transcriptional activity of TCF4 in prostate
cancer and in colon cancer (161), and also in neurons (160). Because FKBP52 is overexpressed
in prostate cancer patients (40), it seems feasible that overexpression of this protein could be a
main reason why β-catenin becomes so active in AR signaling-enhancement in prostate cancer.
In a paper assessing anomalies of β-catenin in human prostate cancer tissues, 23% of all
hormone-dependent prostate cancer tissues showed free (cytoplasmic or nuclear) state β-catenin.
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In almost 39% of all hormone refractory prostate cancer tissues, β-catenin existed in an
abnormally free state (170).
When androgen ablation is utilized as a treatment, it has been suggested that β-catenin
shifts away from the AR signaling pathway to participate in TCF4 signaling, and this could be
the reason for relapse (73). Additionally, acetylation by p300 at K345 on the 6th armadillo repeat
of β-catenin causes enhancement of β-catenin/TCF-4 interactions while causing decreased
binding affinity for AR. In prostate cancer progression, p300 acetylation could either prevent
AR binding directly by β-catenin, as suggested by the Neuveut group (171), or it could
alternatively affect FKBP52’s binding to β-catenin, thereby favoring the binding of TCF-4 over
AR.
Regarding the FKBP52 structural components of synergism, we know that FKBP52’s
PPIase activity is not required for synergism to occur (Figure 2.4A). Also the proline-rich
overhanging loop over the PPIase pocket is an important structure for synergism (Figure 2.4B).
Additionally, FKBP52’s K354 residue which was shown to be critical for FKBP52’s full
regulation of GR and for binding to Hsp90 did not appear to be important for FKBP52/β-catenin
synergism (Figure 2.4C).
The data presented here suggest that we have discovered a novel pathway by which
FKBP52 and β-catenin regulate the androgen receptor independently of the Hsp90 complex.
This is supported by the K354A mutant studies (Figure 2.5C) and the GST pull-down assays
with solely purified β-catenin and FKBP52 (Figure 2.3). Our collaborators’ findings that the βcatenin-AR
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immunoprecipitations suggests that FKBP52 could prime the AR/β-catenin interaction, perhaps
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by altering the orientation of the proteins so that there is a stronger interaction between β-catenin
and AR.
Although crystal structures have not been isolated for the AR/β-catenin/FKBP52
complex, it is apparent through the studies associated with this project that indeed, this complex
is a valid target for prostate cancer studies. β-catenin and FKBP52 might bind together at the
BF3 surface of AR to form a complex with high structural integrity (β-catenin and FKBP52
bound as well as individual bonds of β-catenin to AR and FKBP52 to AR).
Initially, my dissertation project solely focused on characterizing the FKBP52 interaction
with AR. Through random mutagenesis and site-directed mutagenesis based on nuclear receptor
comparisons between receptors regulated by FKBP52 versus those that are not regulated by the
immunophilin, we mutated AR to examine its effects on FKBP52 potentiation events. We found
a number of AR mutations in what is now called the BF-3 surface of the receptor, which caused
receptor dependency upon FKBP52 for signaling (103).

However, it is also feasible that

FKBP52 may not, in fact, bind AR at BF3 as we initially believed, but rather, it might actually
bind β-catenin to help it orient into the correct position to bind the BF3 surface. However, βcatenin does not bind the same subset of nuclear receptors as FKBP52; it only binds AR
similarly (82). β-catenin does bind Retinoic Acid Receptor, Vitamin D Receptor, Retinoid X
Receptor, PPARγ, and ER. The receptors PR, GR, and Thyroid Receptor interact with Wnt
signaling members but not β-catenin directly (172). FKBP52 positively regulates GR (12), PR
(13), and AR (11) but not ER or MR (12) as transcription factors. Since β-catenin and FKBP52
share differing interaction partners with the exception of AR, it is still feasible that FKBP52
could still bind BF3 in the case of FKBP52/ β-catenin synergism and is not indirectly binding
through β-catenin or Hsp90. Regardless of exact placement of β-catenin and FKBP52 on AR, it

110

is obvious that they synergize (Figure 2.2) and that this synergism can be blocked using the BF3
surface inhibitor MJC13 (Figure 3.3).
The MMTV, PSA, and Probasin promoter studies indicated promoter specificity of AR
pathway enhancement when FKBP52 and β-catenin are co-transfected (Figure 2.5). While
these studies are relatively simple, the basic conclusion that can be drawn from these results is
profound. Co-regulation of AR activity by FKBP52 and β-catenin is dependent on the DNA
sequences on which the receptor acts, suggesting that the regulation is occurring at the level of
AR-mediated gene transcription. Not only could this synergism be preferential to particular
DNA sequences, but another theory is that differential recruitment of coactivators and
corepressors could occur in response to FKBP52/β-catenin/AR interactions. Because the effects
are greatest when DHT is present, it suggests that these proteins are synergistic towards AR
activation of the gene and not non-specifically or directly influencing transcription of the
reporter.
5.3 FUTURE DIRECTIONS
Currently, our collaborators in the Fletterick lab at UCSF, are working to generate a
crystal structure of β-catenin and FKBP52 as well as β-catenin, AR, and FKBP52.

This

information is critical for elucidating the mechanism behind the synergistic effect and to
highlighting novel surfaces for the development of therapeutic drug targets for prostate cancer
treatments. Effectively designed FKBP52 inhibitors could block FKBP52/AR interactions or
FKBP52/ β-catenin interactions to stop synergism.
If a crystal structure is not obtained, we can still employ site-directed mutagenesis of the
AR BF-3 surface to target putative binding areas of the receptor based on cross-comparisons of
β-catenin and FKBP binding sites on characterized interaction partners. Following mutations,
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pull down assays or co-immunoprecipitation reactions can be performed to assess binding to
interaction partners. First, we can generate the AR-E893A mutant, which was previously shown
to disrupt AR/β-catenin interactions (81). Secondly, based on structures of binding partners of
the immunophilin FKBP12 (which has a similar FK1 domain and a strikingly similar open
conformation of its proline rich loop to FKBP52), we could mutate exposed Phe or Trp residues
on the AR BF3 surface. It has been noted that the immunophilin FKBP12 directly contacts
Transforming Growth Factor β (TGF-β) receptor, interacting directly through D37, a residue that
is analogous to D68 of FKBP52. When FKBP12 was mutated at either residue 89 or 90 (which
corresponds to amino acids 119 and 120 of FKBP52), TGF-β potentiation ability was severely
decreased.

It also appears that P119 of FKBP12’s proline rich loop becomes intercalated

between W242 and F243 on TGF-β (45). Since the converse residues of FKBP52 are already
established as important functional determinants of AR potentiation and even show importance
in synergism (Figure 2.4B), we believe that residues of the PPIase domain may serve as
interaction surfaces for all FKBPs, and we are interested in finding similar hydrophobic residues
on AR, which may bind with FKBP52. We can screen the BF-3 surface for any exposed Phe or
Trp residues using 3D protein viewers such as UCSF Chimera (Resource for Biocomputing,
Visualization, and Informatics at the University of California, San Francisco (supported by NIH
P41 RR-01081)), and we can mutate these residues specifically and perform functional studies in
the 52 KO MEF cell line to determine which mutants lost potentiation ability of the receptor,
either in conjunction with transfections of AR, β-catenin, and FKBP52; AR and β-catenin, AR
and FKBP52; or AR and vector. Binding studies could also be conducted to determine the
influence of important residues highlighted in functional studies.
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β-catenin interacts with the LBD of the androgen receptor, by virtue of yeast two hybrid
screenings (82), mammalian two hybrid screenings (81), and GST pull-down assays (85). X-ray
crystallography analyses of β-catenin with LRH-1 suggest possible binding to the BF-3 region of
that receptor, and we suspect that it could similarly bind AR. Site-directed mutagenesis of the
fifth armadillo repeat, deemed a crucial domain for interaction between β-catenin and LRH-1
(173), was performed as a part of this project (results not shown). These mutations did not
appear to abrogate FKBP52/β-catenin synergism. However, mutations to other armadillo repeat
domains or other residues besides those in the fifth armadillo repeat could also be examined by
both site-directed mutagenesis and random mutagenesis since the other armadillo repeats have
also been implicated in binding to proteins such as the transcription factor TCF-4 (81). Random
mutants could be screened through yeast reporter assay systems followed by studies of
interesting mutants in 52 KO MEF cell line to determine which mutants lose potentiation ability
of the receptor, either in conjunction with co-transfections with AR and either FKBP52 or vector.
Binding studies could also be conducted to determine the influence of important residues
highlighted in functional studies.
Another collaborator, Paul Webb at Methodist University, is performing analyses to
assist in our understanding of FKBP52/β-catenin interactions at the DNA level.

He is

transfecting FKBP52 and or β-catenin into 22RV1 control versus 52 KD 22RV1 cells, crosslinking the coactivator surface of AR to any bound coactivators, and performing ChIP analysis to
assess differential recruitment of coactivators and/or alterations to binding sites on DNA in
response to FKBP52/β-catenin transfections. Additionally, Dr. Webb is examining genome-wide
expression changes in the presence or absence of MJC13.
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Jane Trepel, a collaborator with the NIH, is able to monitor RNA and protein expression
in prostate tissues from prostate cancer patients. She will help us to conduct RT-PCR analyses
of endogenous gene transcription of AR target genes such as PSA in response to transfections
with FKBP52 and β-catenin or treatments with MJC13. RNA analyses can be supplemented
with protein expression studies and immunohistochemistry analyses to examine translational
changes in these tissues.
Since we were not able to generate β-catenin knockdown cells, an alternative means to
provide a β-catenin negative background would be to employ inhibitors of β-catenin. Many
inhibitors are commercially available, from the inhibitors of Akt/IP3 such as wortmanin or
LY294002 to Wnt inhibitors such as administering a secretory LBD of Frizzled receptor, which
impact the β-catenin signaling cascade. Or novel inhibitors to β-catenin specifically which only
block its interaction with FKBP52 could be developed.
Immunofluorescence microscopy experiments to show the localization of the proteins βcatenin, AR, and FKBP52 within the cell would provide concrete insight into the site of
regulation of the receptor. Attempts to perform nuclear fractionation studies of cells under
different transfection conditions have proven inconclusive (results not shown). It appears that
overall β-catenin expression in the cell is maintained at a constant level, so we theorized that
localization changes occurred in response to transfections of the protein. However, nuclear
fractionation is not the ideal method to study β-catenin.

We are hopeful that confocal

microscopy could prove more consistent and definitive.
Recently, AR has been discovered in about 70% of all breast cancer tissues. AR appears
to play a critical role in triple negative breast cancers. 25% of all breast cancer patients lack PR,
ER, and HER2 receptor but have AR, and it appears that AR is a major activator in these cells

114

(174). It would also be interesting to conduct transfections followed by assays in these cells to
determine if β-catenin, AR, and FKBP52 play a role in this subset of the breast cancer
population.
Lastly, as new drugs are developed to target this synergism, it would be important to
begin trials of these compounds and to examine FKBP52/β-catenin synergism of AR in prostate
cancer mouse xenograft models.
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